Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2015 Oct 6;6:225. doi: 10.3389/fphar.2015.00225

The role of serotonin 5-HT2A receptors in memory and cognition

Gongliang Zhang 1,2,3,*, Robert W Stackman Jr 3,4,*
PMCID: PMC4594018  PMID: 26500553

Abstract

Serotonin 5-HT2A receptors (5-HT2ARs) are widely distributed in the central nervous system, especially in brain region essential for learning and cognition. In addition to endogenous 5-HT, several hallucinogens, antipsychotics, and antidepressants function by targeting 5-HT2ARs. Preclinical studies show that 5-HT2AR antagonists have antipsychotic and antidepressant properties, whereas agonist ligands possess cognition-enhancing and hallucinogenic properties. Abnormal 5-HT2AR activity is associated with a number of psychiatric disorders and conditions, including depression, schizophrenia, and drug addiction. In addition to its traditional activity as a G protein-coupled receptor (GPCR), recent studies have defined novel operations of 5-HT2ARs. Here we review progress in the (1) receptor anatomy and biology: distribution, signaling, polymerization and allosteric modulation; and (2) receptor functions: learning and memory, hallucination and spatial cognition, and mental disorders. Based on the recent progress in basic research on the 5-HT2AR, it appears that post-training 5-HT2AR activation enhances non-spatial memory consolidation, while pre-training 5-HT2AR activation facilitates fear extinction. Further, the potential influence that 5-HT2AR-elicited visual hallucinations may have on visual cue (i.e., landmark) guided spatial cognition is discussed. We conclude that the development of selective 5-HT2AR modulators to target distinct signaling pathways and neural circuits represents a new possibility for treating emotional, neuropsychiatric, and neurodegenerative disorders.

Keywords: serotonin, 5-HT2A receptor, learning, memory, cognition

Introduction

The serotonin (5-HT) 5-HT2A receptor (5-HT2AR) is a GPCR of the type A family. It was defined as the classical D receptor initially by Gaddum and Picarelli (1957), and later referred as the 5-HT2 receptor by Peroutka and Snyder (1979). The 5-HT2AR gene is located on human chromosome 13q14-q21. HTR2A gene codes for a 471-amino acid sequence in rat, mouse, and human (Sparkes et al., 1991). The rat 5-HT2AR was cloned in 1988 (Pritchett et al., 1988) and the human 5-HT2AR was reported by Julius et al. (1990). Central 5-HT2ARs exert diverse behavioral, physiological, and psychological influences (Hoyer et al., 2002; Hannon and Hoyer, 2008; Homberg, 2012). Abnormality in the structure and function of the 5-HT2AR is associated with a number of disorders, including schizophrenia, depression/anxiety, and drug addiction. Furthermore, many hallucinogenic drugs exert their psychoactive effects by acting as agonists for 5-HT2ARs. Preclinical studies show that 5-HT2AR blockade has antipsychotic (Meltzer, 1999), antidepressant (Kroeze and Roth, 1998; Roth et al., 1998) and anxiolytic properties (Cohen, 2005). Pharmacological studies indicate that high-affinity antagonists of 5-HT2ARs are effective atypical antipsychotics, due to their demonstrated efficacy to reduce both positive and negative symptoms of schizophrenia. Results from recent molecular biological and neuropharmacological studies suggest some exciting potential new avenues by which 5-HT2ARs influence CNS function. Here we review progress in understanding the contribution of 5-HT2ARs to modulation of learning and memory through an analysis of their (1) anatomy and biology: distribution, signaling, polymerization, and allosteric modulation; and (2) functions: learning and memory, hallucination and spatial cognition, and mental disorders. Based on the recent progress in 5-HT2AR research, we suggest that selective 5-HT2AR modulators targeting distinct signaling pathways may hold significant efficacy as new therapeutic approaches for several neurological disorders that present with cognitive impairment.

5-HT2AR Anatomy and Biology in CNS

Cellular and Subcellular Distribution

Serotonin 5-HT2ARs are widely distributed in the CNS. In the rat brain, immunohistochemical studies show that 5-HT2ARs are broadly expressed in the cerebral cortex – especially in layers I and IV–V, the piriform and entorhinal cortex, the claustrum, endopiriform nucleus, and olfactory bulb/anterior olfactory nucleus, brainstem, as well as the limbic system and the basal ganglia; especially in the NAc and caudate nucleus (Xu and Pandey, 2000; Hannon and Hoyer, 2008). Interestingly, 5-HT2AR binding appears to be absent from cerebellum (Xu and Pandey, 2000).

In human brain, autoradiographic analysis using [3H] ketanserin indicates a high density of 5-HT2AR binding in laminae III and V of the frontal, parietal, temporal, occipital, anterogenual cortexes, and entorhinal area. 5-HT2ARs are also visualized in the mammillary bodies of the hypothalamus, claustrum, and the lateral nucleus of the amygdala. The hippocampus, caudate, putamen, and accumbens nuclei present an intermediate density of binding. Areas such as the thalamus, brain stem, cerebellum and spinal cord contained only low to very low densities of binding (Pazos et al., 1987). In situ hybridization studies reveal that 5-HT2AR mRNA is present in all neocortical areas, especially in layer 5 pyramidal neurons, and in putative interneurons. 5-HT2AR mRNA was observed at minimal levels in the hippocampus and not in the raphe, cerebellum, substantia nigra or striatum (Burnet et al., 1995).

Morphological and double immunofluorescence analyses confirmed the presence of 5-HT2ARs on pyramidal neurons, interneurons, and glial cells in neocortex, amygdala and hippocampus (Willins et al., 1997; Bombardi, 2012, 2014). Thus, predicting the functional influence of activated cortical 5-HT2ARs is not straightforward, since these receptors would be capable of direct excitation and modulating feed-forward inhibition. In addition, 5-HT2ARs are located on cholinergic (Quirion et al., 1985) and glutamatergic neurons (Hasuo et al., 2002). 5-HT2AR immunolabeling was also observed on glial cells in many forebrain regions: astrocytes were identified by double immunolabeling as cells in which 5-HT2AR and GFAP was colocalized (Xu and Pandey, 2000); and on microglia (Glebov et al., 2015). These findings demonstrate that consideration of the serotonin-mediated signaling at 5-HT2ARs must include pathways that involve neurons and glial cells alike. It will be of interest to determine the degree to which functional influences expressed by the activation of 5-HT2ARs are dependent upon neurons, astrocytes, and microglial cells, and to determine whether clinically relevant features of 5-HT2ARs are related to changes in neurons or astrocytes.

At the subcellular level, 5-HT2AR immunolabeling is found on cell bodies and processes of neurons (Cornea-Hebert et al., 1999; Xu and Pandey, 2000); in particular, at both pre- and post-synaptic compartments (Miner et al., 2003). However, the majority of evidence suggests a predominant expression at postsynaptic dendritic spines and shafts of non-5-HT neurons. Our own immuno-electron microscopy data revealed that 5-HT2AR is also distributed in the dendritic spines, shafts, and presynaptic terminals of CA1 neurons in the mouse dorsal hippocampus (Zhang et al., 2015). Consideration should also be given to evidence suggesting that 5-HT2AR subunits are extensively and dynamically trafficked between the cytoplasm and the neuronal membrane, as much 5-HT2AR label has been identified at cytoplasmic rather than membrane bound compartments in adult rat neocortex (Cornea-Hebert et al., 1999). It will be of interest to determine the corresponding function of 5-HT2AR subunit trafficking between the respective neuronal sub-compartments, and the intracellular signaling that promotes trafficking.

Interacting Proteins

Multiple interacting proteins regulate the function of 5-HT2ARs in the membrane. 5-HT2ARs interact with multiple PDZ protein-1 (MUPP1) and PSD-95 PDZ proteins (Jones et al., 2009). The 5-HT2AR colocalizes with PSD-95 and with MUPP1 in a subset of dendritic spines of rat cortical pyramidal neurons. PDZ proteins are vital for docking 5-HT2AR to the dendrites in cortical neurons and preventing the internalization of 5-HT2ARs (Xia et al., 2003). MUPP1 is enriched in dendritic spine PSD domains of pyramidal neurons and enhances the localization of 5-HT2AR to the cell surface. Within cortical pyramidal neurons, PSD-95 regulates the functional activity of 5-HT2AR by promoting apical dendritic targeting and stabilizing receptor turnover. The complex of 5-HT2AR and PSD-95 plays a key role in 5-HT2AR-mediated head-twitch behavior in mice (Abbas et al., 2009). Binding of calmodulin to the 5-HT2AR C-terminus impedes PKC-mediated phosphorylation of the 5-HT2AR, thus, preventing its desensitization (Turner and Raymond, 2005). Conversely, association of p90-RSK2 with 5-HT2AR (intracellular 3 loop) silences the GPCR’s signaling (Sheffler et al., 2006). Caveolin-1 interacts with 5-HT2AR and profoundly modulates its signaling by facilitating the interaction of 5-HT2AR with Gαq (Bhatnagar et al., 2004). 5-HT2AR and the light chain 2 domain of the microtubule-associated protein MAP1A are co-localized in the intracellular compartment of pyramidal neuronal dendrites of adult rats and may participate in intraneuronal signaling processes involving cytoskeletal elements (Cornea-Hebert et al., 2002). In consideration of these properties, we suggest that altering 5-HT2AR-coupled proteins and pathways may enable an alternative method to selectively promote distinct modulatory functions of 5-HT2ARs.

Signaling

Activation of neuronal 5-HT2ARs can induce pleiotropic effects via G protein-dependent, ligand-dependent, and ligand-independent signaling pathways, including phospholipase signaling, ERK pathway, and tyrosine kinase pathway in neurons (Millan et al., 2008; Masson et al., 2012). In most circumstances, activation of 5-HT2ARs increases intracellular Ca2+ levels via Gαq-PLC-IP3 signaling (Hagberg et al., 1998). In PFC, activation of 5-HT2ARs suppresses membrane Cav1.2 L-type Ca2+ currents via a Gαq-mediated PLCβ/IP3/calcineurin signaling pathway (Day et al., 2002). 5-HT2AR activation also stimulates the Gα12/13-phospholipase A2 signal transduction pathway, which promotes arachidonic acid release (Kurrasch-Orbaugh et al., 2003a,b).

Besides PLC-mediated Ca2+ signaling, 5-HT2AR activation also induces ERK phosphorylation via diverse intracellular signaling mechanisms (Gooz et al., 2006). Src and calmodulin promote 5-HT2AR-mediated phosphorylation of ERK. In the PC12 cell model system, ERK phosphorylation by 5-HT2AR may not depend on PLC/PKC signaling, and instead requires an increase in intracellular Ca2+, and the activation of CaM and Src (Quinn et al., 2002). The ERK target RSK2 directly acts on the third intracellular (i3) loop of 5-HT2AR protein (Sheffler et al., 2006), leading to direct phosphorylation of the i3 loop at the conserved residue Ser-314 to suppress 5-HT2AR signaling. In addition, RSK2 is required for tyrosine kinases, such as the epidermal growth factor receptor and the platelet-derived growth factor receptor, both of which have been demonstrated to attenuate 5-HT2AR functioning in primary cortical neurons (Strachan et al., 2009, 2010).

Besides the G protein, 5-HT2ARs are also coupled to β-arrestin2. 5-HT binds 5-HT2AR to stimulate Akt phosphorylation via the β-arrestin2/phosphoinositide 3-kinase/Src/Akt cascade (Schmid and Bohn, 2010). Application of the 5-HT2AR agonist DOI to cultured cortical neurons induced phosphorylation of p21-activated kinase (PAK) via Rac guanine nucleotide exchange factor (RacGEF) kalirin-7 (Jones et al., 2009). The 5-HT2AR also regulates the tyrosine kinase pathway activity (Quinn et al., 2002). Excitation of neuronal 5-HT2ARs activates transglutaminase which leads to transamidation of Rac1, a small G protein, resulting in constitutive activation of Rac1 (Dai et al., 2008). Chronic treatment with olanzapine, an atypical antipsychotic drug, causes the desensitization of 5-HT2AR signaling. In rat frontal cortex, stimulation of the JAK-STAT pathway desensitizes the 5-HT2AR-mediated PLC activation induced by olanzapine (Singh et al., 2010). Furthermore, constitutive activation of 5-HT2ARs induces Gq/11 phosphorylation and desensitization (uncoupling) (Shi et al., 2007).

As indicated above, 5-HT2ARs are also expressed in microglia and mediate 5-HT-induced exosome release (Glebov et al., 2015). Activation of 5-HT2AR increases intracellular Ca2+ via PLC signaling in astrocytes (Hagberg et al., 1998) and Glu efflux from C6 glioma cells (Meller et al., 2002). Considering the diversity of signaling cascades that can be triggered by 5-HT2AR activation, it is perhaps not surprising that serotonergic activation of 5-HT2ARs can have diverse influences on neuronal responses and CNS functions.

Oligomerization

The GPCRs can form homomers and heteromers, and thereby present distinct signaling and functional activities (Rios et al., 2001). Consistent with this, 5-HT2ARs have been shown to form oligomers (Lukasiewicz et al., 2010). Fluorescence resonance energy transfer and immunoprecipitation studies revealed that the human 5-HT2AR homodimerizes in cultured cells (Brea et al., 2009). For 5-HT2AR oligomers, the 5-HT2AR agonist DOI caused an increase in energy transfer efficiency to the level of 12%, and ketanserin caused a decrease of 4.4%. Heterodimers of 5-HT2AR and dopamine D2 receptors respond to DOI and quinpirole, a DA D2R agonist, with a decrease in FRET efficiency, while ketanserin and butaclamol increase the transfer efficiency value (Lukasiewicz et al., 2010). Heterodimers of 5-HT2AR and mGluR2 receptor form via the linking domain in transmembrane-4 and -5 segments, and are present in the human brain. Post-mortem studies indicate a reduced density of these functional complexes in brains of schizophrenics (Gonzalez-Maeso et al., 2008). Delta-9-tetrahydrocannabinol (THC), the main psychoactive compound of marijuana, induces memory impairments, anxiety, dependence, and analgesia. Vinals et al. (2015) recently reported that amnesic and anxiolytic effects, but not analgesia, induced by THC were suppressed in 5-HT2AR knockout mice. Molecular studies revealed that cannabinoid CB1 receptors (CB1R) and the 5-HT2AR physically interact with each other to form heteromers, which are distributed extensively in hippocampus, cortex, and dorsal striatum, but not in the NAc. In vivo experiments have revealed that stimulation of CB1R and 5-HT2AR reduces cell signaling, and the binding of an antagonist to one receptor blocks signaling of the interacting receptor. Heteromer formation leads to a switch in 5-HT2AR-mediated G-protein coupling from Gαq to Gi. Synthetic peptides with the sequence of transmembrane helices 5 and 6 of CB1R disrupt CB1R and 5-HT2AR heteromerization in vivo, leading to a selective abrogation of memory impairments, but not the antinociceptive properties caused by THC exposure (Vinals et al., 2015). The anatomy, biology and function of 5-HT2AR homomers and heteromers, including the dynamic formation and dissociation, distribution, signaling and function, remain elusive. Elucidation of 5-HT2AR oligomers will be interesting for both basic science research and potential clinical applications.

Allosteric Modulation

Recent years have witnessed a tremendous advance in the research and development of novel compounds for GPCRs that bind allosteric sites to regulate receptor structure and function. These ligands provide high specificity, novel modes of efficacy and may open up a novel avenue for therapeutic agents against multiple mental and neurological disorders. Allosteric modulators bind to a site distinct from that of the orthosteric ligand-binding site. Usually the allosteric modulator induces a structure change within the GPCR to enhance or suppress the orthosteric ligand’s functional activity (Conn et al., 2009; Melancon et al., 2012). Application of the amidated lipid, oleamide significantly potentiated 5-HT-induced hydrolysis of phosphoinositide in pituitary P11 cells expressing endogenously 5-HT2ARs (Thomas et al., 1997). Taken together, these results indicate that there are several binding sites present on 5-HT2ARs, and we suggest that it will be of interest to further characterize the functional significance of the distinct ligand-driven actions at the 5-HT2AR.

Constitutive Activity

As mentioned above, 5-HT2ARs can also be constitutively active (i.e., via activating the receptor in an agonist-independent activity) in vivo (Berg et al., 2008). The inverse 5-HT2AR agonists (e.g., risperidone and ketanserin) produce a great suppression of basal IP production, leading to a reduction of basal activity in the C322K mutant 5-HT2AR (Egan et al., 1998). The “constitutively active” arrestin mutant (Arr2-R169E) induces agonist-independent 5-HT2AR internalization, and a constitutive translocation of the Arr2-R169E mutant to the plasma membrane (Gray et al., 2003). The constitutive activity of 5-HT2ARs may represent another mechanism of regulating cellular function. The specific relationships of these constitutively active 5-HT2AR-mediated properties to distinct behaviors have not been determined.

Electrophysiological Characteristics

Electrophysiological studies reveal complex effects of 5-HT2AR activation on cortical neurons; however, mainly these receptors appear to mediate depolarizing effects on excitatory and inhibitory neurons. Slice recordings from prefrontal cortical neurons indicate depolarizing effects following 5-HT2AR activation (Aghajanian and Marek, 1999; Zhou and Hablitz, 1999; Avesar and Gulledge, 2012). Local application of DOI, a 5-HT2A/2C receptor agonist, increases the firing rates of cortical neurons (Stein et al., 2000) and facilitates synaptic plasticity through an NMDAR-dependent mechanism in presumptive pyramidal neurons of the rat BLA (Chen et al., 2003). Meanwhile, α-methyl-5-hydroxytryptamine (a 5-HT2R agonist) and DOI induce activation of GABAergic interneurons of the rat BLA (Stein et al., 2000). Double immunofluorescence labeling demonstrated that the 5-HT2AR is primarily localized to parvalbumin-containing BLA interneurons. Accordingly, 5-HT primarily acts on 5-HT2ARs to potentiate GABAergic inhibition. 5-HT2AR activation increases the frequency and amplitude of sIPSCs recorded from the pyramidal neurons in BLA of the juvenile rat (Jiang et al., 2009). DOI potentiates NMDAR-mediated changes in membrane potentials and calcium influx without affecting the neuronal resting membrane potential or input resistance. However, DOI does not affect AMPA/kainate receptor-mediated excitatory synaptic responses (Chen et al., 2003). The relationship of 5-HT2ARs to NMDARs is consistent with the view that 5-HT2ARs may be an effective target for modulating experience-dependent synaptic plasticity in the CNS. Globally, 5-HT2ARs have been shown to influence low-frequency field potential oscillations in rat frontal cortex (Celada et al., 2008). Taken together, these findings demonstrate that the 5-HT2AR mediates 5-HT-induced excitation of cortical neurons. However, much remains to be determined as to the neurophysiological consequences of 5-HT2AR activation, in particular as they relate to the regulation of specific behaviors.

Recent molecular and pharmacological research has made significant advances in the understanding of the functional selectivity of 5-HT2AR. The multiple signaling pathways suggests bias agonism and bias signaling of 5-HT2ARs, which posit that an agonist can produce a mix of signaling, which is potentially determined by cell type and functional status.

5-HT2AR Functions in CNS

Long-term declarative or episodic memory is supported by a network of brain structures in the medial temporal lobe of the mammalian brain. The medial temporal lobe memory system, which includes the hippocampus, dentate gyrus, and surrounding extrahippocampal cortical regions, influence decision-making processes guided by the PFC, and posterior parietal cortex (Squire et al., 2004, 2007; Preston and Eichenbaum, 2013). Serotonergic fibers originating from the raphe nuclei innervate many of the critical nodes within the medial temporal lobe memory system, including the hippocampus and amygdala, and on to the PFC (Vertes, 1991; Vertes et al., 1999). The modulatory influence of 5-HT on simple and more complex forms of learning and memory has been extensively examined in both invertebrate and vertebrate model systems (Kandel and Squire, 2000). The relevance of 5-HT to memory seems to generalize across mammals:, dietary tryptophan increases brain 5-HT levels and improves memory in rodents (Khaliq et al., 2006), the elderly, AD patients, and schizophrenics (Levkovitz et al., 2003; Porter et al., 2003). Further, reductions in brain 5-HT concentrations after acute or chronic tryptophan depletion has been demonstrated to impair contextual fear memory in mice (Uchida et al., 2007), object memory in rats (Jenkins et al., 2009), and declarative memory in humans (Schmitt et al., 2006). Below, we describe some evidence suggesting that the 5-HT2AR may hold special significance as one of the substrates by which 5-HT regulates learning and memory (Meneses, 2007).

Learning and Memory

Polymorphisms in the human HTR2A gene are associated with altered memory processes. For example, a HTR2A gene polymorphism inducing the substitution of the His452 on the receptor subunit to a Tyr residue is associated with a significant impairment in memory recall amongst adults (de Quervain et al., 2003; Sigmund et al., 2008; Zhu et al., 2013). Carriers of the His452Tyr (rs6314) exhibited poor verbal delayed recall and recognition, but performed equivalent to controls on tests of immediate recall, attentional, and executive function (Wagner et al., 2008). Compared to His homozygotes, Tyr carriers exhibited a diminished hippocampal response to novel stimuli and a higher tendency to judge novel stimuli as familiar during delayed recognition (Schott et al., 2011). Amongst schizophrenics and healthy controls, those carriers of homozygous CC (T102C) and GG (A-1438G), or carriers of the so-called T-allele (rs6314), of the HTR2A gene polymorphisms exhibited significantly impaired short-term verbal memory (Alfimova et al., 2009), and spatial working memory (Blasi et al., 2013). Another polymorphism in the HTR2A gene, referred to as rs4941573 was found to be predictive of increased error rate in a spatial working memory task in an adult Chinese subject population (Gong et al., 2011). These results provide just a brief and incomplete view of a broad literature indicating the impressive degree to which alterations in the HTR2A gene relate to disordered cognitive functions in normal and abnormal human subjects.

The regional distribution of 5-HT2ARs can be predictive of the memory capacities that are sensitive to serotonin manipulation. The 5-HT2ARs are widely expressed in the neocortex and hippocampus of rats (Xu and Pandey, 2000; Hannon and Hoyer, 2008), rabbits (Aloyo and Harvey, 2000), primates (Jakab and Goldman-Rakic, 1998; Lopez-Gimenez et al., 1998), and humans (Hoyer et al., 1986; Lopez-Gimenez et al., 1998). Table 1 summarizes the major findings of studies in which the learning and memory effects were examined after 5-HT2AR pharmacological manipulations across distinct tasks and different species. The inconsistency of experimental results may be attributed to the species, selectivity and dose of drug, behavioral task and other effectors.

Table 1.

Reported effects on learning and memory after pharmacological manipulation of 5-HT2A receptors (5-HT2ARs).

Drug Route; dose Task Species Effect Reference
M100907 0.01–0.1 mg/kg; i.p. Probabilistic reversal learning Mice ↑Acquisition Amodeo et al., 2014;
BTBR T+tf/J mouse model of autism
M100907 0.01–0.1 mg/kg; i.p. Serial spatial reversal learning task Rats ↓ Retrieval Boulougouris et al., 2008
M100907 0.02–2.0 nmol; olfactory bulb Reversal-learning task Rats ↓ Acquisition Furr et al., 2012
MDL 11,939 0.067–6.7 μmol/kg; s.c. Nictitating membrane conditioned responses Rabbits ↓ Acquisition Welsh et al., 1998
MDL 11,939 300 ng/μl; mPFC NOR task Rats ↓ Retrieval Bekinschtein et al., 2013
Ritanserin, 2.5 mg/kg × 11 days; s.c. Conditioned olfactory training Rat pup ↑ Acquisition McLean et al., 1996
Risperidone 1 mg/kg; i.p. Reward-dependent operant conditioning task Rats ↓ Acquisition and ↑ extinction Frick et al., 2015
Risperidone 0.125 mg; i.p. Probabilistic reversal learning B6 mice ↓ Acquisition Amodeo et al., 2014
Ketanserin Methysergide 1.0–3.0 mg/kg; s.c.;
3.0–15.0 mg/kg; i.p.
Delayed non-matching to position task (working memory) Rats ↔ Retrieval Ruotsalainen et al., 1997
Ketanserin 0.1 mg/kg × 14 days; i.p. Passive avoidance paradigm and MWM Rats ↓ Acquisition Fedotova and Ordyan, 2010
DOI Ketanserin 0.01–0.1 mg/kg; i.p.
0.001–0.1 mg/kg, i.p.
Autoshaping learning task Rats ↑ Consolidation Meneses et al., 1997
M100907;
α-methyl-5-HT
PFC Oculomotor delayed-response tasks Monkeys ↓ Acquisition
↑ Acquisition
Williams et al., 2002
TCB-2 1.0 mg/kg; i.p. NOR task and Trace and delay fear conditioning Mice ↑ Object memory acquisition; ↑fear memory extinction Zhang et al., 2013
DOI 0.1–0.3 mg/kg; i.p. Autoshaping learning task Rats ↓ Consolidation Meneses, 2007
LSD 0.43–12.9 μg/side; hippocampus Trace eyeblink conditioning. Rabbits ↑ Acquisition Romano et al., 2010
LSD 1–300 nmol/kg; i.v. Nictitating membrane response Rabbit ↑ Acquisition Gimpl et al., 1979
LSD 0.13 mg/kg/d × 11 days; s.c. Bulbectomy-induced deficit in active avoidance learning Rats ↑ Acquisition Buchborn et al., 2014
Psilocybin 215 μg/kg; oral Spatial working memory task Humans ↔ Retrieval Carter et al., 2005
Psilocybin 0.1–1.5 mg/kg, i.p. Trace fear conditioning - mice ↑ Extinction Catlow et al., 2013
Psilocin 1.0 mg/kg, i.p.
4.0 mg/kg, i.p.
MWM;
Carousel maze (CM)
Rats ↓Acquisition of CM;
↓Retrieval of MWM (4 mg/kg);
↔ Consolidation
Rambousek et al., 2014
Quipazine 1.25–10 mg/kg, s.c. Conditioned avoidance response Rats ↑ Acquisition Alhaider et al., 1993

↑, enhance; ↓, suppress; ↔, no effect.

Object Memory

The spontaneous NOR task, which relies on rodents’ inherent preference for exploring novel over familiar stimuli, has become a popular method for examining the neuropharmacological and neurophysiological mechanisms of object memory (Ennaceur, 2010; Cohen and Stackman, 2015). In the task, rodents are exposed to one or two novel objects in a familiar enclosure during a sample session (i.e., training). The rodent is removed from the enclosure after it has sufficiently explored the objects. After a delay of some length, the rodent is returned to the enclosure for a memory test session, during which the enclosure contains one familiar object and a novel object. If the rodent has successfully encoded and consolidated the memory of the original object from the sample session, then it is expected that the rodent will preferentially explore the novel object during the test session. The NOR task offers advantages for testing rodent memory in that the distinct memory processes of encoding, consolidation and retrieval are operationally defined as events occurring during the sample session, after the sample session, or during the test session, respectively. Another advantage is that the behavioral responses are spontaneous rather than requiring overt motivation such as electrical shock or food restriction. Our recent studies implicate the hippocampus as a key region in the rodent brain for object memory processes (Cohen et al., 2013; Cohen and Stackman, 2015). In light of the fact that 5-HT2ARs are densely expressed in the hippocampus (Luttgen et al., 2004), we examined the contribution of hippocampal 5-HT2ARs in object memory processes in male mice using an NOR task (see Figure 1). Systemic activation of 5-HT2ARs with the selective agonist, TCB-2 after the sample session significantly enhanced the time mice spent exploring the new object presented during the test session 24 h later (Zhang et al., 2013). The memory-enhancing effect of TCB-2, was blocked by pretreatment with the 5-HT2AR antagonist, MDL 11,939, which suggests that 5-HT2AR activation enhances the consolidation of object memory. Interestingly, when TCB-2 was administrated before the sample session, or before the test session, the 5-HT2AR agonist failed to increase novel object preference relative to the respective control group. Together, these data suggest that 5-HT2AR activation selectively potentiates memory consolidation. Furthermore, the selective local microinfusion of TCB-2 into the CA1 region of dorsal hippocampus recapitulated the memory enhancing effect observed after systemic treatment (Zhang et al., 2015). The relevance of the 5-HT2AR for object memory processes was also demonstrated by results of a study showing that the local infusion of the 5-HT2AR antagonist MDL 11,939 into the mPFC impaired retrieval of object-in-context memory in rats (Bekinschtein et al., 2013). Interestingly, the 5-HT2AR agonist DOI was found to impair retrieval of memory for an operant response by adult rats in an autoshaping task (Meneses, 2007). Thus, it would appear that the influence of the 5-HT2AR on memory is task- and memory system-dependent, and perhaps by the underlying neural circuitry that supports the respective memory process.

FIGURE 1.

FIGURE 1

Activation of 5-HT2ARs enhances the consolidation of object memory. (A) Experimental strategy. Left, during the sample session, mice were allowed to explore two identical novel objects each for at least 15 s, or either one for 18 s within a 10-min sample session. Middle, during the test session 24 h later, one of the objects (a cabinet leveling foot) was replaced with a novel object (a plastic toy monkey) and mice were individually reintroduced to the arena. Right, the objects used in this study. (B) There was no difference in the latency to achieve exploration criteria during the sample session between the saline- and TCB-2-treated mice. (C) Mice that received TCB-2 right after the sample session exhibited a significantly stronger preference for exploring the novel object during the test session: analysis revealed that TCB-2-treated mice had a higher mean discrimination ratio as compared to that of the saline group. (D) MDL 11,939, a selective 5-HT2AR blocker suppressed TCB-2-induced enhancement in object memory (Zhang et al., 2013). p < 0.05, vs. respective control condition.

The encoding and consolidation of hippocampal-dependent memory appears, in part, to require fast glutamatergic neurotransmission, ensuing phases of synaptic plasticity, and dynamic replay of experience-dependent neurophysiological oscillatory activity within hippocampal cell populations (Eichenbaum, 1999; Karlsson and Frank, 2009). Our published (Zhang et al., 2013) data show that post-training activation of 5-HT2AR s enhances object memory, likely by affecting consolidation. Prevailing views state that the hippocampus transfers recent to-be-remembered information to the neocortex during sharp wave ripples of the hippocampal local field potential (i.e., 100–200 Hz ripples; Chrobak and Buzsaki, 1996; Carr et al., 2011). During sleep, hippocampal neurons ‘replay’ patterns of spike trains present during a learning episode. As sharp wave ripples and replay may represent systems consolidation of memory, it would be of interest to examine the influence of 5-HT2AR-sensitive drugs on sharp wave ripples and replay of spiking sequences during sleep episodes after a to-be-remembered experience. Postsynaptic 5-HT2ARs may modulate object memory consolidation by also influencing NMDAR-mediated synaptic plasticity. Consistent with this possibility, hippocampal 5-HT2ARs are predominantly expressed at dendritic sites on pyramidal neurons (Cornea-Hebert et al., 1999; Peddie et al., 2008). 5-HT2AR-containing dendritic processes also were immunolabeled for the NMDAR subunit NR1 and GluR2 (Peddie et al., 2008). We have found that 5-HT2AR activation increased the extracellular efflux of glutamate in the dorsal hippocampus, and increased the basal firing rates of CA1 pyramidal neurons in awake behaving mice (Zhang et al., 2015). These results suggest that the 5-HT2AR activation induced facilitation of object memory consolidation, may result from the potentiation of hippocampal glutamate release, and pyramidal neuron temporal dynamics at a critical post-training time period. These data suggest that the 5HT2AR may serve as a drug target for pharmacological interventions to treat memory impairments. It is conceivable that 5-HT2AR activation promotes an increase in intracellular Ca2+, combined with NMDAR-mediated Ca2+ influx, which together would facilitate the behavior-initiated synaptic plasticity. Aghajanian and Marek (1999) reported that activation of 5-HT2AR produces an elevation in the frequency and amplitude of neuronal sEPSP/sEPSC. Consistently, 5-HT2AR activation has been shown to facilitate NMDAR activity and synaptic plasticity in the cortex (Arvanov et al., 1999) and BLA (Chen et al., 2003). Furthermore, 5-HT2AR directly interacts with PSD-95 to regulate receptor trafficking and signaling (Xia et al., 2003). 5-HT2AR activation induces a transient increase in dendritic spinogenesis (Yoshida et al., 2011), phosphorylation of PAK, neuronal Rac guanine nucleotide exchange factor (Jones et al., 2009), BDNF expression (Vaidya et al., 1997), and Erk mitogen-activated protein kinase activity (Florian and Watts, 1998; Watts, 1998). Finally, the 5-HT2AR inverse agonist pimavanserin was shown to reverse NMDAR antagonism-induced object memory impairments in combination with atypical antipsychotic drugs (Snigdha et al., 2010). These results support the view of a modulatory influence of 5-HT2AR on NMDAR-dependent memory mechanisms. Considering the myriad potential influences of 5-HT2AR on medial temporal lobe memory mechanisms, there would appear to be multiple downstream influences by which 5-HT2AR activation could enhance memory.

Fear Memory

While there is a rich literature on the influence of serotonin on anxiety and an established contribution of serotonergic drugs to the remediation of anxiety disorders in humans, the present review will focus on the influence of 5-HT2ARs on fear memory encoded during Pavlovian conditioning sessions. Pavlovian fear conditioning has become a popular procedure for examining the neurobiological mechanisms of fear memory. As a Pavlovian conditioning procedure, fear conditioning lends itself well to defining processes of encoding, consolidation and retrieval of fear memory. Fear conditioning taxes a well-defined neural circuit within the amygdala, which in turn interacts with the hippocampus, anterior cingulate, or the PFC, depending on the elements of the conditioning session and the stage of memory processing (Zelikowsky et al., 2014). In addition, considerable attention has been given to investigations of the underlying biology of extinction of fear memory. During a delay fear conditioning session, an innocuous stimulus (e.g., a neutral tone or light) becomes a CS when it is repeatedly presented in such a way that it co-terminates with the presentation of a sufficiently aversive US (e.g., foot shock) (Zhang et al., 2013). The unconditioned response to the foot shock US is typically jumping and running, but the conditioned response to the CS is a defensive freezing response, or the cessation of all movement except for respiration. Thus, the freezing behavior provides a reliable post-conditioning measure of fear memory in rodents (Blanchard and Blanchard, 1969). During fear conditioning, the subject learns to associate the tone CS with the foot shock US, and under certain conditions, learns to associate the foot shock with the environment or context where the conditioning session was presented. Acquisition of both the tone-shock and the context-shock associations requires the amygdala; however, the context-shock associations are also dependent upon the hippocampus (Kim and Fanselow, 1992; Phillips and LeDoux, 1992). There has been considerable debate regarding the involvement of the hippocampus in contextual fear memory since there have been reports that hippocampal lesions impair contextual fear memory (Kim and Fanselow, 1992; Phillips and LeDoux, 1992; Anagnostaras et al., 1999; Stiedl et al., 2000), and others reporting that such lesions spare contextual fear memory (Cho et al., 1999; Wiltgen et al., 2006). Consensus seems to be building for the view that if the rodent is permitted sufficient time to acquire a hippocampal-dependent configural representation of the context (the chamber’s geometry, olfactory, visual, tactile, and auditory cues) before the US is presented, then the hippocampus is engaged in associating the contextual memory with the foot shock (Rudy et al., 2002, 2004; Matus-Amat et al., 2004; Zelikowsky et al., 2014). In a trace fear conditioning procedure, a temporal gap is imposed between the offset of the tone CS and the onset of the foot shock US. The acquisition of an appropriately timed (i.e., anticipatory) conditioned freezing response occurs progressively over the course of the repeated CS–US pairings; this temporal fear memory is a form of declarative memory dependent on intact hippocampal function in rodents and humans (Clark and Squire, 1998; McEchron et al., 1998; Chowdhury et al., 2005). It should be clear that in deciphering an influence of 5-HT2AR-sensitive drugs on the distinct processes of memory for contextual and/or cued fear, one must consider the specifics of the conditioning protocol used.

Finally, considerable attention has been directed toward defining the mechanisms of fear memory extinction, in part because of extinction’s potential relationship to components of the human disorder post-traumatic stress disorder (Jovanovic and Ressler, 2010). Repeated presentations of the CS alone to the fear-conditioned rodent, promotes the acquisition of a new inhibitory association, which dampens or completely suppresses the expression of conditioned fear responses. Distinct subregions of the rodent PFC contribute differentially to fear extinction; that is, the prelimbic cortex appears to influence the expression of fear responses, while the infralimbic cortex influences the acquisition of extinction of fear memory (Quirk et al., 2010; Sierra-Mercado et al., 2011). Synaptic plasticity within mPFC-BLA neuronal circuits is induced during fear extinction training, resulting in increased inhibition of CS-elicited activity of BLA extinction neurons (Herry et al., 2008, 2010). Thus, converging evidence implicates the infralimbic and prelimbic cortices of the rodent brain and their differential projections to the amygdala sub-regions and to the hippocampus as contributing significantly to the synaptic plasticity that develops during the acquisition of fear extinction (see Tovote et al., 2015 for a recent review).

We found that systemic administration of the 5-HT2AR agonist TCB-2 (see Figure 2) significantly enhanced the acquisition of fear extinction in mice that had undergone trace fear conditioning or delay fear conditioning (Zhang et al., 2013). Importantly, the 5-HT2AR agonist did not affect locomotor responses or baseline freezing in the mice. Therefore, the effect of TCB-2 on fear extinction appeared to be specific to facilitating the acquisition of the new inhibitory memory that suppressed fear expression. It is of interest to determine the site of action in the rodent brain at which TCB-2 works to facilitate fear extinction. In light of the plastic changes in neural circuitry that occur during the acquisition of fear extinction, it is possible that TCB-2 influences either the infralimbic cortical neurons or the “extinction neurons” of the BLA to facilitate fear extinction. Izumi and colleagues reported that an amygdala-selective reduction of 5-HT content via site-specific 5,7-DHT injection reduced the expression of conditioned fear responses in rats (Izumi et al., 2012). While this finding is difficult to reconcile with our report that 5-HT2AR activation enhanced fear extinction, it is possible that the 5-HT denervation may have increased postsynaptic expression of 5-HT2ARs in the amygdala, which might in turn impair the expression of fear. It is clear that further studies are needed to clarify the neurophysiological influences of 5-HT, and the 5-HT2AR in particular, on the neural circuitry supporting fear memory encoding, consolidation, retrieval, and extinction.

FIGURE 2.

FIGURE 2

Stimulation of 5-HT2ARs enhances the acquisition of extinction of trace fear memory. (A) Left, a chamber for fear conditioning (Context A) and contextual fear memory test; right, Context B, a modified chamber with different color, context, light density, and odor for cued fear memory test. (B) Trace fear conditioning training procedure. After a 60-s habitation to Context A, a tone was presented for 15 s followed by 30 s stimulus-free interval, and then a 0.5-s, 0.75 mA foot shock (US) was presented. The CS–US pairing was repeated eight times with a 210-s intertrial interval (ITI). Mice were removed from the conditioning chamber and returned to their home cages 60 s after the final CS–US pairing. Trace fear conditioning extinction procedure. Sixty seconds after placing the mouse into the modified chamber, eight unpaired 15-s tone CS were presented with a 120-s ITI. (C) Mice that received TCB-2 (1.0 mg/kg, i.p.) before a trace fear memory extinction test exhibited accelerated acquisition of extinction as indicated by significantly lower freezing scores earlier in the course of extinction as compared to those of vehicle-treated mice. TCB-2 significantly decreased percent freezing from the second to eighth CS presentation (Zhang et al., 2013).

The influence of the 5-HT2AR on the extinction and reconsolidation of fear memory may have significant impact on the development of therapeutic approaches for subjects with fear memory invasion, such as phobias and post trauma stress disorder (Quirk et al., 2010). For decades, the pharmacological manipulation of the 5-HT system has been a useful approach to treat emotional and mental disorders, such as depression and anxiety. Recent progress has suggested a promising therapeutic application of hallucinogenic 5-HT2 agonists to treat depression and anxiety (Grob et al., 2011). These results suggest that despite the historical stigma associated with 5-HT2AR activators as potential hallucinogens, such compounds may provide important medical potential for treating affective and cognitive symptoms associated with emotional and mental conditions.

Glutamatergic neurons in the amygdala, cortex and hippocampus are essential for memory extinction and reconsolidation. Local infusion of NMDAR antagonists into the BLA or CA1 region of hippocampus before extinction training suppresses fear memory extinction and reconsolidation (Baker and Azorlosa, 1996; Szapiro et al., 2003). The NMDAR partial agonist D-cycloserine facilitates the extinction of fear memory (Walker et al., 2002; Ledgerwood et al., 2003). Knockout of NMDAR in hippocampal CA1 pyramidal cells exclusively impairs the establishment of conditioning between the CS and the US during a trace fear conditioning task. These results suggest that the CS representation and conditioning are entrained within hippocampus cell ensembles, probably via NMDAR-dependent synaptic plasticity (McHugh et al., 1996; Huerta et al., 2000). Recall that 5-HT2ARs are expressed in the dendrites and dendritic spines of dentate gyrus neurons where NMDARs and AMPARs are assumed to be located (Peddie et al., 2008). 5-HT2AR activation produces an elevation in the frequency and amplitude of cortical neuronal sEPSP/sEPSCs (Aghajanian and Marek, 1999), facilitates NMDAR activity and synaptic plasticity in the cortex (Arvanov et al., 1999) and BLA (Chen et al., 2003). It is worth while to examine the degree to which NMDARs expressed in the infralimbic and prelimbic cortices contribute to the 5HT2AR-mediated enhancement in fear extinction.

Converging evidence demonstrates that activation of 5-HT2ARs via systemic injection, or by local microinfusion, appears to enhance two forms of hippocampal-dependent memory in mice: object memory and conditioned fear memory. Administration of a selective 5-HT2AR antagonist alone was not found to significantly affect object memory or fear memory (Zhang et al., 2013), suggesting that memory consolidation does not require serotonergic activation of 5-HT2ARs and/or the antagonists do not affect the tonic effect the 5-HT2AR. Activation of 5-HT2ARs with TCB-2 was also found to facilitate fear memory extinction in mice. These results offer promising support for the view that the 5-HT2AR may be an important new target for consideration in the search for mechanisms by which long-term memory can be enhanced in humans.

Hallucination vs. Spatial Cognition

5-HT2AR and Hallucination

Recent evidence suggests that activation of 5-HT2ARs may promote experiencing visual hallucinations by increasing neuronal excitability and altering visual-evoked cortical responses (Kometer et al., 2013). Hallucination is a type of misperception defined as the perception of an object without there being an object to perceive. Hallucinations are a significant characteristic found in a diversity of psychiatric and neurological states. Hallucinations can be triggered by at least three categories of drugs: psychedelics, (i.e., DOI, TCB-2, LSD, and psilocybin) via activation of 5-HT2ARs, psychostimulants (i.e., cocaine or amphetamine) via activation of dopamine D2 receptors and dissociative anesthetics (i.e., phencyclidine or ketamine) via blockade of glutamate NMDARs. The signaling and behavioral responses to each hallucinogen are distinct from each other. Activation of 5-HT2AR is critical for the psilocybin (found in magic mushroom)-induced α oscillations, N170 visual-evoked potentials, and visual hallucinations (Kometer et al., 2013).

5-hydroxytryptamine/serotonin is an endogenous neurotransmitter and is not considered hallucinogenic. Interesting, N-methyltryptamines, a metabolite of 5-HT, also presents high affinity for 5-HT2AR and can induce hallucinations in a manner independent of β-arrestin2/phosphoinositide 3-kinase/Src/Akt cascade (Schmid and Bohn, 2010). Signaling for hallucinogens is distinct. Lisuride (an antiparkinsonian agent) and LSD both bind cortical 5-HT2AR, and thereby regulate PLC activity. LSD signaling involves pertussis toxin-sensitive heterotrimeric Gi/o proteins and Src (Gonzalez-Maeso et al., 2007). Non-hallucinogenic agonists, for example lisuride, only stimulate cortical Gq in rats, whereas hallucinogens such as psilocybin (found in magic mushrooms), and LSD stimulate both Gq/11 and Gi (Gonzalez-Maeso et al., 2007). The β-arrestin pathway is involved in hallucinogen-mediated head shake responses in rodents (Schmid et al., 2008), and 5-HT induces a head shake response in mice via a β-arrestin-2-dependent signaling. However, the DOI invoked head shake behavior is not dependent upon β-arrestin-2 signaling. These findings suggest that the 5-HT2AR-β-arrestin interaction may be exclusively for endogenous 5-HT action. Further examination of hallucinogen-mediated signaling may have major implications in drug development for treating emotional and mental disorders such as depression and schizophrenia (Schmid et al., 2008). More research efforts will need to be focused on the hallucination-inducing aspects of 5-HT2AR-sensitive drugs and, relevant to their potential therapeutic potential, it may be important to consider designing novel compounds that yield more of the beneficial effects, without activating those problematic sensory and perceptual effects.

5-HT2AR-mediated Hallucination and Spatial Cognition

5-HT2A receptors may affect spatial cognition. A human population-based study shows that 5-HT2AR TT genotype of rs6313 is associated with better spatial cognitive performance (Gong et al., 2011). Kant et al. (1998) reported that the 5-HT2AR agonist DOI (0.1 and 0.25 mg/kg, 30 min pretreatment) slowed rat performance as assessed by swim time on both a well-learned water maze as well as learning of a new maze, but DOI did not alter error rate on either task. Kant concluded that DOI impaired performance by suppressing motor activity on a water maze (Kant et al., 1998), which was in opposition to another report showing that manipulation of 5-HT2AR did not impair the latency to a visible platform water maze test (Naghdi and Harooni, 2005). The serotonergic hallucinogens may impair the hippocampal-dependent spatial cognition by acting on 5-HT2ARs (Naghdi and Harooni, 2005). However, the direct evidence of 5-HT2AR on visuospatial cognition and the central target has not been determined.

Serotonergic psychedelics may affect the integrity of visual functioning. Visual-directed spatial cognition and navigation are guided by exteroceptive (e.g., landmarks) and interoceptive (e.g., self-motion information) cues, and their integration. The hippocampus is a pivotal brain region receiving and integrating information for spatial memory and navigation in rodents (Broadbent et al., 2004; Eichenbaum, 2004). The MWM is a classic behavioral task for testing hippocampal-dependent visuospatial cognition, including place learning and memory, orientation and decision-making (Morris et al., 1982; Morris, 1984). Further, hippocampal place cells exhibit location-specific firing, and are considered to be fundamental components of network for spatial problem solving in the mammalian brain (for a review see Moser et al., 2008). The hippocampal neural circuit representing current location, directional heading and its integration is influenced by exteroceptive and interoceptive cues, and is considered to guide spatial cognition and navigation.

We recently found that pre-test activation of 5-HT2AR with TCB-2 significantly delayed the initiation of an accurate search path by well-trained male mice in the hidden platform MWM (Zhang et al., 2015). Importantly, 5-HT2AR activation did not affect swim performance or visual cue-triggered approach behavior in the visible platform water maze task. Taken together, our results suggest that the activation of 5-HT2AR impairs the retrieval of hippocampal spatial memory, but not the accuracy of spatial information retrieval and decision-making. It is conceivable that the delayed initiation of accurate spatial search by TCB-2-treated mice might reflect the possible visual hallucinatory influences of the 5-HT2AR agonist. For example, perhaps TCB-2-induced a brief aberration of visual input that slowed the perception of current position and local view of the mouse at the start of the water maze probe test. Once, reconciled or reoriented, the mouse was able to swim accurately to the remembered spatial location of the platform. It will be of interest to determine where in the brain TCB-2 is acting to alter spatial memory retrieval. The relatively weak influence of TCB-2-induced visual hallucination on spatial navigation may due to the difference in the visual information passing through the brain and central targets processing the information.

Taken together, the results we have reported here of memory effects after activation of the 5-HT2AR represent a fairly complex picture. The post-training administration of TCB-2 enhanced consolidation of object memory in mice. Pre-test administration of TCB-2 did not affect retrieval of object memory, yet delayed retrieval of spatial memory. Pre-extinction training administration of TCB-2 facilitated the acquisition of extinction of both trace and delay fear memories. The facilitating effect of TCB-2 on fear extinction may have been the result of a combined effect of suppressing fear expression – possibly a consequence of impaired retrieval of fear memory, and enhancing the encoding and consolidation of fear extinction. To characterize the 5-HT2AR agonist as a cognitive enhancer based solely on our object memory results, would be to ignore the other experimental findings. We are interested in conducting a more comprehensive analysis of the impact of TCB-2 on multiple forms of memory. For example, it will be interesting to examine whether post-conditioning TCB-2 might enhance the consolidation of fear memory, in a manner consistent with that observed in the NOR task. Likewise, it will be interesting to test whether post-extinction training TCB-2 facilitates the consolidation of fear extinction. Results of these experiments will help in better appreciating the modulatory influence of the 5-HT2AR on long-term memory processes. This synthesis of recent findings of the influences of 5-HT2AR activation should provide a credible argument that the 5-HT2AR participates significantly to the well-documented contribution of 5-HT to memory (Meneses, 2013).

5-HT2AR and Mental Disorders

A number of psychiatric and neurodegenerative disorders are associated with the variation of structure, expression, and function of 5-HT2ARs. Positron emission tomography (PET) molecular imaging has the sensitivity to quantify binding of 5-HT2ARs in CNS disorders. Medication-free depressed subjects presented greater 5-HT2AR binding (Bhagwagar et al., 2006). There was a significant reduction in 5-HT2AR binding in frontal polar, dorsolateral and medial frontal cortex, and parietal and temporal associative cortex of OCD patients and a significant correlation between 5-HT2AR availability in orbitofrontal and dorsolateral frontal cortex and clinical severity (Perani et al., 2008). Schizophrenia patients present with very high 5HT2AR occupancy in the frontal cortex (Talvik-Lotfi et al., 2000). These results suggest that the variation in the number, affinity and/or function of 5-HT2AR participates in the etiology of mental disorders.

Alzheimer’s Disease

It is interesting to note that neocortical 5-HT2AR binding is significantly decreased in patients with early stage AD, and in those with mild cognitive impairment; especially in temporal lobe regions associated with long-term memory (Meltzer et al., 1998; Hasselbalch et al., 2008; Santhosh et al., 2009; Marner et al., 2011, 2012). Further, the severity of cognitive impairment in AD patients correlates with the decrease in 5-HT2AR binding (Versijpt et al., 2003). Given the pattern of 5-HT2AR distribution in neocortical regions and their expression on principal excitatory neurons, it is possible that the marked reduction in 5-HT2AR in brains of AD is a direct product of neuron loss in key brain regions. Consistent with evidence from the human studies, the Alzheimer’s-like neuropathology and associated memory deficits in rodents, which follow intra-hippocampal injection of ß-amyloid(1-42), are associated with a significant reduction in levels of hippocampal 5-HT2AR expression (Christensen et al., 2008). Although we have focused this analysis on the influence of 5-HT2ARs on long-term, hippocampal-dependent memory, there is clear and compelling evidence to suggest that the 5-HT2AR represents a potential new target by which human long-term memory may be modulated. We assert that it will be of interest in further examine the contribution of 5-HT2ARs to memory processes, and we are particularly interested in determining neurophysiological influences of 5-HT2AR agonists which promote the enhancement of memory consolidation which we have reported in mice.

Drug Memory

Drug dependence, classified as an impulsive, compulsive, and relapsing psychiatric disorder, represents a devastating societal problem worldwide. The profound symptoms of drug abuse, in particular the cue-elicited relapse to drug use after even long periods of abstinence, are a consequence of robust experience-dependent synaptic plasticity within the brain’s reward circuit. Like episodic, semantic, and habit memory, drug-associated memories are persistent and hold a strong influence on current and future behaviors. Of particular interest is the consideration of memory extinction as a psychological tool for remediating the problem of relapse in drug addicts. That is, if the problem of drug abuse is approached as a mental disorder of memory, then pharmacological manipulations that facilitate extinction may hold therapeutic utility for treating drug abuse. Drug exposure alters the expression and function of 5-HT2AR, for example morphine decreases frontocortical 5-HT2AR binding affinity in dogs (Adriaens et al., 2012). 5-HT2Rs are up-regulated in amygdala, midbrain, pons, and medulla of morphine-tolerant and -dependent rats, but not in morphine-abstinent rats (Gulati and Bhargava, 1989). There is considerable evidence that 5-HT2ARs modulate the behavioral consequences of repeated exposure to addictive psychomotor stimulants. For example, M100907 suppresses hyperactivity elicited by cocaine (Fletcher et al., 2002), MK-801, amphetamine (O’Neill et al., 1999), and morphine (Auclair et al., 2004). DOM, a 5-HT2AR agonist, attenuates locomotor-stimulating effects of morphine, which could be prevented by M100907 (Li et al., 2013). Furthermore, M100907 attenuated the ability of experimenter-administered cocaine to reinstate lever pressing (Fletcher et al., 2002) and attenuated the drug associated cue-induced reinstatement of cocaine-seeking behavior after extinction (Nic Dhonnchadha et al., 2009). M100907 also suppressed reinstatement induced by nicotine prime or nicotine-associated cue (Fletcher et al., 2012) and sensitization (Zaniewska et al., 2010). Intra-NAc infusions of M 100907 blocked the expression of cocaine-induced locomotor sensitization (Zayara et al., 2011). Intra-PFC M100907 decreased cue-elicited reinstatement of cocaine seeking-behavior (Pockros et al., 2011). Together, these results suggest that 5-HT2ARs modulate drug addiction-dependent behaviors such as craving and drug-seeking and pharmacological blockade of 5-HT2ARs may represent a therapeutic advance in suppression of cue-evoked craving and/or relapse in drug addicts.

Therapeutic Application of 5-HT2AR

Preclinical and clinical studies have provided support for the use of pharmacological manipulation of 5-HT2AR to treat the symptoms of mental disorders. Activation of 5-HT2AR with TCB-2 in the medial septum-diagonal band of Broca complex enhances neuronal activity and working memory in hemiparkinsonian rats (Li et al., 2015). M100907 had no effect on attentional performance, but abolished the PCP-induced attentional performance deficits in rats (Poyurovsky et al., 2003). M100907 prevents impairment in attentional performance by NMDAR blockade in the rat PFC (Mirjana et al., 2004). There are a number of 5-HT2AR drugs that have been evaluated or are being currently evaluated under clinical trials, for example quetiapine1 for schizophrenia; M1009072 for depression; ACP-1033 for Parkinson’s disease; pimavanserin for patients with AD psychosis4 or with Parkinson’s disease psychosis5.

Conclusion

In this review, we have summarized recent progress in the signaling, polymerization and allosteric modulation of 5-HT2AR; and have discussed the critical role of 5-HT2ARs in a number of cognitive processes. Based on the results of studies from our lab and others, it appears that activation of 5-HT2ARs may offer a novel approach to treat the impairment of learning and memory associated with several neurodegenerative disorders. Meanwhile, blockade of 5-HT2AR may offer a feasible way to suppress drug craving and/or relapse. It will be very interesting to identify the corresponding signaling pathways by which 5-HT2ARs modulate these behavioral capacities. Of particular note, we reviewed evidence that 5-HT2ARs may dimerize with other receptors, and that certain pathways may promote constitutive activation of 5-HT2ARs, which likely represent novel receptor signaling influences. Connecting such novel properties of 5-HT2ARs to distinct functional consequences of 5-HT-, or agonist-, specific activation of the 5-HT2ARs will be important for improving understanding the myriad influences of 5-HT2ARs in the CNS. The development of highly selective 5-HT2AR ligands will be essential for further establishing the critical involvement of the 5-HT2AR for a number of fundamental cognitive behaviors.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This project was supported by the NSF (IBN 0630522) and NIH (MH 086591) and a Researcher of the Year award from the Division of Research at Florida Atlantic University to RS and National Natural Science Foundation general projects from China (81271217, 81471161), Ph.D. Start Fund from Anhui Medical University (XJ201405) to GZ.

Abbreviations

5-HT

5-hydroxytryptamine/serotonin

AD

Alzheimer disease

AMPAR

alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor

BLA

basolateral amygdala

CS

conditioned stimulus

DOI

1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane

ERK

extracellular signal-regulated kinases

GFAP

glial fibrillary acidic protein

GPCR

G protein-coupled receptor

IP2

inositol phosphate

LSD2

lysergic acid diethylamide

mGluR2

metabotropic glutamate receptor

MUPP1

multiple PDZ protein-1

MWM

Morris water maze

NAc

nucleus accumbens

NMDAR

N-methyl-D-aspartate receptor

NOR

novel object recognition

OCD

obsessive–compulsive disorder

PDZ

postsynaptic density zone

PFC

prefrontal cortex

PKC

protein kinase C

PLC

phospholipase C

PSD

postsynaptic density

RSK2

ribosomal S6 kinase 2

sIPSC

spontaneous inhibitory postsynaptic current

sIPSP

spontaneous inhibitory postsynaptic potential

US

unconditioned stimulus

Footnotes

References

  1. Abbas A. I., Yadav P. N., Yao W. D., Arbuckle M. I., Grant S. G., Caron M. G., et al. (2009). PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J. Neurosci. 29 7124–7136. 10.1523/JNEUROSCI.1090-09.2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Adriaens A. M., Polis I. E., Vermeire S. T., Waelbers T., Duchateau L., Sys S. U., et al. (2012). The influence of morphine on cerebral 5-HT2A availability in dogs: a SPECT study. J. Nucl. Med. 53 1969–1973. 10.2967/jnumed.112.103796 [DOI] [PubMed] [Google Scholar]
  3. Aghajanian G. K., Marek G. J. (1999). Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res. 825 161–171. 10.1016/S0006-8993(99)01224-X [DOI] [PubMed] [Google Scholar]
  4. Alfimova M. V., Monakhov M. V., Abramova L. I., Golubev S. A., Golimbet V. E. (2009). [Serotonin receptor (5-HTR2A) and dysbindin (DTNBP1) genes and component process variables of short-term verbal memory in schizophrenia]. Zh. Nevrol. Psikhiatr. Im. S.S Korsakova 109 70–75. [PubMed] [Google Scholar]
  5. Alhaider A. A., Ageel A. M., Ginawi O. T. (1993). The quipazine- and TFMPP-increased conditioned avoidance response in rats: role of 5HT1C/5-HT2 receptors. Neuropharmacology 32 1427–1432. 10.1016/0028-3908(93)90040-A [DOI] [PubMed] [Google Scholar]
  6. Aloyo V. J., Harvey J. A. (2000). Antagonist binding at 5-HT(2A) and 5-HT(2C) receptors in the rabbit: high correlation with the profile for the human receptors. Eur. J. Pharmacol. 406 163–169. 10.1016/S0014-2999(00)00645-2 [DOI] [PubMed] [Google Scholar]
  7. Amodeo D. A., Jones J. H., Sweeney J. A., Ragozzino M. E. (2014). Risperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf/J mice. Autism Res. 7 555–567. 10.1002/aur.1395 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Anagnostaras S. G., Maren S., Fanselow M. S. (1999). Temporally graded retrograde amnesia of contextual fear after hippocampal damage in rats: within-subjects examination. J. Neurosci. 19 1106–1114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Arvanov V. L., Liang X., Magro P., Roberts R., Wang R. Y. (1999). A pre- and postsynaptic modulatory action of 5-HT and the 5-HT2A, 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex. Eur. J. Neurosci. 11 2917–2934. 10.1046/j.1460-9568.1999.00708.x [DOI] [PubMed] [Google Scholar]
  10. Auclair A., Drouin C., Cotecchia S., Glowinski J., Tassin J. P. (2004). 5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. Eur. J. Neurosci. 20 3073–3084. 10.1111/j.1460-9568.2004.03805.x [DOI] [PubMed] [Google Scholar]
  11. Avesar D., Gulledge A. T. (2012). Selective serotonergic excitation of callosal projection neurons. Front. Neural Circuits 6:12 10.3389/fncir.2012.00012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Baker J. D., Azorlosa J. L. (1996). The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning. Behav. Neurosci. 110 618–620. 10.1037/0735-7044.110.3.618 [DOI] [PubMed] [Google Scholar]
  13. Bekinschtein P., Renner M. C., Gonzalez M. C., Weisstaub N. (2013). Role of medial prefrontal cortex serotonin 2A receptors in the control of retrieval of recognition memory in rats. J. Neurosci. 33 15716–15725. 10.1523/JNEUROSCI.2087-13.2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Berg K. A., Harvey J. A., Spampinato U., Clarke W. P. (2008). Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression. Prog. Brain Res. 172 287–305. 10.1016/S0079-6123(08)00914-X [DOI] [PubMed] [Google Scholar]
  15. Bhagwagar Z., Hinz R., Taylor M., Fancy S., Cowen P., Grasby P. (2006). Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. Am. J. Psychiatry 163 1580–1587. [DOI] [PubMed] [Google Scholar]
  16. Bhatnagar A., Sheffler D. J., Kroeze W. K., Compton-Toth B., Roth B. L. (2004). Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected Galphaq-coupled protein receptors. J. Biol. Chem. 279 34614–34623. 10.1074/jbc.M404673200 [DOI] [PubMed] [Google Scholar]
  17. Blanchard R. J., Blanchard D. C. (1969). Passive and active reactions to fear-eliciting stimuli. J. Comp. Physiol. Psychol. 68 129–135. 10.1037/h0027676 [DOI] [PubMed] [Google Scholar]
  18. Blasi G., De Virgilio C., Papazacharias A., Taurisano P., Gelao B., Fazio L., et al. (2013). Converging evidence for the association of functional genetic variation in the serotonin receptor 2a gene with prefrontal function and olanzapine treatment. JAMA Psychiatry 70 921–930. 10.1001/jamapsychiatry.2013.1378 [DOI] [PubMed] [Google Scholar]
  19. Bombardi C. (2012). Neuronal localization of 5-HT2A receptor immunoreactivity in the rat hippocampal region. Brain Res. Bull. 87 259–273. 10.1016/j.brainresbull.2011.11.0068 [DOI] [PubMed] [Google Scholar]
  20. Bombardi C. (2014). Neuronal localization of the 5-HT2 receptor family in the amygdaloid complex. Front. Pharmacol. 5:68 10.3389/fphar.2014.0006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Boulougouris V., Glennon J. C., Robbins T. W. (2008). Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology 33 2007–2019. 10.1038/sj.npp.1301584 [DOI] [PubMed] [Google Scholar]
  22. Brea J., Castro M., Giraldo J., Lopez-Gimenez J. F., Padin J. F., Quintian F., et al. (2009). Evidence for distinct antagonist-revealed functional states of 5-hydroxytryptamine(2A) receptor homodimers. Mol. Pharmacol. 75 1380–1391. 10.1124/mol.108.054395 [DOI] [PubMed] [Google Scholar]
  23. Broadbent N. J., Squire L. R., Clark R. E. (2004). Spatial memory, recognition memory, and the hippocampus. Proc. Natl. Acad. Sci. U.S.A. 101 14515–14520. 10.1073/pnas.0406344101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Buchborn T., Schroder H., Hollt V., Grecksch G. (2014). Repeated lysergic acid diethylamide in an animal model of depression: normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling. J. Psychopharmacol. 28 545–552. 10.1177/0269881114531666 [DOI] [PubMed] [Google Scholar]
  25. Burnet P. W., Eastwood S. L., Lacey K., Harrison P. J. (1995). The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res. 676 157–168. 10.1016/0006-8993(95)00104-X [DOI] [PubMed] [Google Scholar]
  26. Carr M. F., Jadhav S. P., Frank L. M. (2011). Hippocampal replay in the awake state: a potential substrate for memory consolidation and retrieval. Nat. Neurosci. 14 147–153. 10.1038/nn.2732 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Carter O. L., Burr D. C., Pettigrew J. D., Wallis G. M., Hasler F., Vollenweider F. X. (2005). Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J. Cogn. Neurosci. 17 1497–1508. 10.1162/089892905774597191 [DOI] [PubMed] [Google Scholar]
  28. Catlow B. J., Song S., Paredes D. A., Kirstein C. L., Sanchez-Ramos J. (2013). Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp. Brain Res. 228 481–491. 10.1007/s00221-013-3579-0 [DOI] [PubMed] [Google Scholar]
  29. Celada P., Puig M. V., Diaz-Mataix L., Artigas F. (2008). The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: reversal by antipsychotic drugs. Biol. Psychiatry 64 392–400. 10.1016/j.biopsych.2008.03.013 [DOI] [PubMed] [Google Scholar]
  30. Chen A., Hough C. J., Li H. (2003). Serotonin type II receptor activation facilitates synaptic plasticity via N-methyl-D-aspartate-mediated mechanism in the rat basolateral amygdala. Neuroscience 119 53–63. 10.1016/S0306-4522(03)00076-9 [DOI] [PubMed] [Google Scholar]
  31. Cho Y. H., Friedman E., Silva A. J. (1999). Ibotenate lesions of the hippocampus impair spatial learning but not contextual fear conditioning in mice. Behav. Brain Res. 98 77–87. 10.1016/S0166-4328(98)00054-0 [DOI] [PubMed] [Google Scholar]
  32. Chowdhury N., Quinn J. J., Fanselow M. S. (2005). Dorsal hippocampus involvement in trace fear conditioning with long, but not short, trace intervals in mice. Behav. Neurosci. 119 1396–1402. 10.1037/0735-7044.119.5.1396 [DOI] [PubMed] [Google Scholar]
  33. Christensen R., Marcussen A. B., Wortwein G., Knudsen G. M., Aznar S. (2008). Abeta(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT(2A) levels. Exp. Neurol. 210 164–171. 10.1016/j.expneurol.2007.10.009 [DOI] [PubMed] [Google Scholar]
  34. Chrobak J. J., Buzsaki G. (1996). High-frequency oscillations in the output networks of the hippocampal- entorhinal axis of the freely behaving rat. J. Neurosci. 16 3056–3066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Clark R. E., Squire L. R. (1998). Classical conditioning and brain systems: the role of awareness. Science 280 77–81. 10.1126/science.280.5360.77 [DOI] [PubMed] [Google Scholar]
  36. Cohen H. (2005). Anxiolytic effect and memory improvement in rats by antisense oligodeoxynucleotide to 5-hydroxytryptamine-2A precursor protein. Depress. Anxiety 22 84–93. 10.1002/da.20087 [DOI] [PubMed] [Google Scholar]
  37. Cohen S. J., Munchow A. H., Rios L. M., Zhang G., Asgeirsdottir H. N., Stackman R. W., Jr. (2013). The rodent hippocampus is essential for nonspatial object memory. Curr. Biol. 23 1685–1690. 10.1016/j.cub.2013.07.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Cohen S. J., Stackman R. W., Jr. (2015). Assessing rodent hippocampal involvement in the novel object recognition task. A review. Behav. Brain Res. 285 105–117. 10.1016/j.bbr.2014.08.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Conn P. J., Christopoulos A., Lindsley C. W. (2009). Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 8 41–54. 10.1038/nrd2760 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Cornea-Hebert V., Riad M., Wu C., Singh S. K., Descarries L. (1999). Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J. Comp. Neurol. 409 187–209. [DOI] [PubMed] [Google Scholar]
  41. Cornea-Hebert V., Watkins K. C., Roth B. L., Kroeze W. K., Gaudreau P., Leclerc N., et al. (2002). Similar ultrastructural distribution of the 5-HT(2A) serotonin receptor and microtubule-associated protein MAP1A in cortical dendrites of adult rat. Neuroscience 113 23–35. 10.1016/S0306-4522(02)00146-X [DOI] [PubMed] [Google Scholar]
  42. Dai Y., Dudek N. L., Patel T. B., Muma N. A. (2008). Transglutaminase-catalyzed transamidation: a novel mechanism for Rac1 activation by 5-hydroxytryptamine2A receptor stimulation. J. Pharmacol. Exp. Ther. 326 153–162. 10.1124/jpet.107.135046 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Day M., Olson P. A., Platzer J., Striessnig J., Surmeier D. J. (2002). Stimulation of 5-HT(2) receptors in prefrontal pyramidal neurons inhibits Ca(v)1.2 L type Ca(2+) currents via a PLCbeta/IP3/calcineurin signaling cascade. J. Neurophysiol. 87 2490–2504. [DOI] [PubMed] [Google Scholar]
  44. de Quervain D. J., Henke K., Aerni A., Coluccia D., Wollmer M. A., Hock C., et al. (2003). A functional genetic variation of the 5-HT2a receptor affects human memory. Nat. Neurosci. 6 1141–1142. 10.1038/nn1146 [DOI] [PubMed] [Google Scholar]
  45. Egan C., Herrick-Davis K., Teitler M. (1998). Creation of a constitutively activated state of the 5-HT2A receptor by site-directed mutagenesis: revelation of inverse agonist activity of antagonists. Ann. N. Y. Acad. Sci. 861 136–139. 10.1111/j.1749-6632.1998.tb10184.x [DOI] [PubMed] [Google Scholar]
  46. Eichenbaum H. (1999). The hippocampus and mechanisms of declarative memory. Behav. Brain Res. 103 123–133. 10.1016/S0166-4328(99)00044-3 [DOI] [PubMed] [Google Scholar]
  47. Eichenbaum H. (2004). Hippocampus: cognitive processes and neural representations that underlie declarative memory. Neuron 44 109–120. 10.1016/j.neuron.2004.08.028 [DOI] [PubMed] [Google Scholar]
  48. Ennaceur A. (2010). One-trial object recognition in rats and mice: methodological and theoretical issues. Behav. Brain Res. 215 244–254. 10.1016/j.bbr.2009.12.036 [DOI] [PubMed] [Google Scholar]
  49. Fedotova Y. O., Ordyan N. E. (2010). Blockade of 5-HT2A/2C-type receptors impairs learning in female rats in the course of estrous cycle. Bull. Exp. Biol. Med. 150 6–8. 10.1007/s10517-010-1053-6 [DOI] [PubMed] [Google Scholar]
  50. Fletcher P. J., Grottick A. J., Higgins G. A. (2002). Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology 27 576–586. [DOI] [PubMed] [Google Scholar]
  51. Fletcher P. J., Rizos Z., Noble K., Soko A. D., Silenieks L. B., Le A. D., et al. (2012). Effects of the 5-HT2C receptor agonist Ro60-0175 and the 5-HT2A receptor antagonist M100907 on nicotine self-administration and reinstatement. Neuropharmacology 62 2288–2298. 10.1016/j.neuropharm.2012.01.023 [DOI] [PubMed] [Google Scholar]
  52. Florian J. A., Watts S. W. (1998). Integration of mitogen-activated protein kinase kinase activation in vascular 5-hydroxytryptamine2A receptor signal transduction. J. Pharmacol. Exp. Ther. 284 346–355. [PubMed] [Google Scholar]
  53. Frick L. R., Bernardez-Vidal M., Hocht C., Zanutto B. S., Rapanelli M. (2015). Dual role of serotonin in the acquisition and extinction of reward-driven learning: involvement of 5-HT1A, 5-HT2A and 5-HT3 receptors. Behav. Brain Res. 277 193–203. 10.1016/j.bbr.2014.06.025 [DOI] [PubMed] [Google Scholar]
  54. Furr A., Lapiz-Bluhm M. D., Morilak D. A. (2012). 5-HT2A receptors in the orbitofrontal cortex facilitate reversal learning and contribute to the beneficial cognitive effects of chronic citalopram treatment in rats. Int. J. Neuropsychopharmacol. 15 1295–1305. 10.1017/S1461145711001441 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Gaddum J. H., Picarelli Z. P. (1957). Two kinds of tryptamine receptor. Br. J. Pharmacol. Chemother. 12 323–328. 10.1111/j.1476-5381.1957.tb00142.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Gimpl M. P., Gormezano I., Harvey J. A. (1979). Effects of LSD on learning as measured by classical conditioning of the rabbit nictitating membrane response. J. Pharmacol. Exp. Ther. 208 330–334. [PubMed] [Google Scholar]
  57. Glebov K., Lochner M., Jabs R., Lau T., Merkel O., Schloss P., et al. (2015). Serotonin stimulates secretion of exosomes from microglia cells. Glia 63 626–634. 10.1002/glia.22772 [DOI] [PubMed] [Google Scholar]
  58. Gong P., Li J., Wang J., Lei X., Chen D., Zhang K., et al. (2011). Variations in 5-HT2A influence spatial cognitive abilities and working memory. Can. J. Neurol. Sci. 38 303–308. 10.1017/S0317167100011513 [DOI] [PubMed] [Google Scholar]
  59. Gonzalez-Maeso J., Ang R. L., Yuen T., Chan P., Weisstaub N. V., Lopez-Gimenez J. F., et al. (2008). Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452 93–97. 10.1038/nature06612 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Gonzalez-Maeso J., Weisstaub N. V., Zhou M., Chan P., Ivic L., Ang R., et al. (2007). Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53 439–452. 10.1016/j.neuron.2007.01.008 [DOI] [PubMed] [Google Scholar]
  61. Gooz M., Gooz P., Luttrell L. M., Raymond J. R. (2006). 5-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-alpha-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells. J. Biol. Chem. 281 21004–21012. 10.1074/jbc.M512096200 [DOI] [PubMed] [Google Scholar]
  62. Gray J. A., Bhatnagar A., Gurevich V. V., Roth B. L. (2003). The interaction of a constitutively active arrestin with the arrestin-insensitive 5-HT(2A) receptor induces agonist-independent internalization. Mol. Pharmacol. 63 961–972. 10.1124/mol.63.5.961 [DOI] [PubMed] [Google Scholar]
  63. Grob C. S., Danforth A. L., Chopra G. S., Hagerty M., Mckay C. R., Halberstadt A. L., et al. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch. Gen. Psychiatry 68 71–78. 10.1001/archgenpsychiatry.2010.116 [DOI] [PubMed] [Google Scholar]
  64. Gulati A., Bhargava H. N. (1989). Brain and spinal cord 5-HT2 receptors of morphine-tolerant-dependent and -abstinent rats. Eur. J. Pharmacol. 167 185–192. 10.1016/0014-2999(89)90578-5 [DOI] [PubMed] [Google Scholar]
  65. Hagberg G. B., Blomstrand F., Nilsson M., Tamir H., Hansson E. (1998). Stimulation of 5-HT2A receptors on astrocytes in primary culture opens voltage-independent Ca2+ channels. Neurochem. Int. 32 153–162. 10.1016/S0197-0186(97)00087-9 [DOI] [PubMed] [Google Scholar]
  66. Hannon J., Hoyer D. (2008). Molecular biology of 5-HT receptors. Behav. Brain Res. 195 198–213. 10.1016/j.bbr.2008.03.020 [DOI] [PubMed] [Google Scholar]
  67. Hasselbalch S. G., Madsen K., Svarer C., Pinborg L. H., Holm S., Paulson O. B., et al. (2008). Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol. Aging 29 1830–1838. 10.1016/j.neurobiolaging.2007.04.011 [DOI] [PubMed] [Google Scholar]
  68. Hasuo H., Matsuoka T., Akasu T. (2002). Activation of presynaptic 5-hydroxytryptamine 2A receptors facilitates excitatory synaptic transmission via protein kinase C in the dorsolateral septal nucleus. J. Neurosci. 22 7509–7517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Herry C., Ciocchi S., Senn V., Demmou L., Muller C., Luthi A. (2008). Switching on and off fear by distinct neuronal circuits. Nature 454 600–606. 10.1038/nature07166 [DOI] [PubMed] [Google Scholar]
  70. Herry C., Ferraguti F., Singewald N., Letzkus J. J., Ehrlich I., Luthi A. (2010). Neuronal circuits of fear extinction. Eur. J. Neurosci. 31 599–612. 10.1111/j.1460-9568.2010.07101.x [DOI] [PubMed] [Google Scholar]
  71. Homberg J. R. (2012). Serotonin and decision making processes. Neurosci. Biobehav. Rev. 36 218–236. 10.1016/j.neubiorev.2011.06.001 [DOI] [PubMed] [Google Scholar]
  72. Hoyer D., Hannon J. P., Martin G. R. (2002). Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71 533–554. 10.1016/S0091-3057(01)00746-8 [DOI] [PubMed] [Google Scholar]
  73. Hoyer D., Pazos A., Probst A., Palacios J. M. (1986). Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Res. 376 97–107. 10.1016/0006-8993(86)90903-0 [DOI] [PubMed] [Google Scholar]
  74. Huerta P. T., Sun L. D., Wilson M. A., Tonegawa S. (2000). Formation of temporal memory requires NMDA receptors within CA1 pyramidal neurons. Neuron 25 473–480. 10.1016/S0896-6273(00)80909-5 [DOI] [PubMed] [Google Scholar]
  75. Izumi T., Ohmura Y., Futami Y., Matsuzaki H., Kubo Y., Yoshida T., et al. (2012). Effects of serotonergic terminal lesion in the amygdala on conditioned fear and innate fear in rats. Eur. J. Pharmacol. 696 89–95. 10.1016/j.ejphar.2012.09.028 [DOI] [PubMed] [Google Scholar]
  76. Jakab R. L., Goldman-Rakic P. S. (1998). 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. Natl. Acad. Sci. U.S.A. 95 735–740. 10.1073/pnas.95.2.735 [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Jenkins T. A., Elliott J. J., Ardis T. C., Cahir M., Reynolds G. P., Bell R., et al. (2009). Tryptophan depletion impairs object-recognition memory in the rat: reversal by risperidone. Behav. Brain Res. 208 479–483. 10.1016/j.bbr.2009.12.030 [DOI] [PubMed] [Google Scholar]
  78. Jiang X., Xing G., Yang C., Verma A., Zhang L., Li H. (2009). Stress impairs 5-HT2A receptor-mediated serotonergic facilitation of GABA release in juvenile rat basolateral amygdala. Neuropsychopharmacology 34 410–423. 10.1038/npp.2008.71 [DOI] [PubMed] [Google Scholar]
  79. Jones K. A., Srivastava D. P., Allen J. A., Strachan R. T., Roth B. L., Penzes P. (2009). Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc. Natl. Acad. Sci. U.S.A. 106 19575–19580. 10.1073/pnas.0905884106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Jovanovic T., Ressler K. J. (2010). How the neurocircuitry and genetics of fear inhibition may inform our understanding of PTSD. Am. J. Psychiatry 167 648–662. 10.1176/appi.ajp.2009.09071074 [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Julius D., Huang K. N., Livelli T. J., Axel R., Jessell T. M. (1990). The 5HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors. Proc. Natl. Acad. Sci. U.S.A. 87 928–932. 10.1073/pnas.87.3.928 [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Kandel E. R., Squire L. R. (2000). Neuroscience: breaking down scientific barriers to the study of brain and mind. Science 290 1113–1120. 10.1126/science.290.5494.1113 [DOI] [PubMed] [Google Scholar]
  83. Kant G. J., Wylie R. M., Chu K., Ghosh S. (1998). Effects of the serotonin agonists 8-OH-DPAT, buspirone, and DOI on water maze performance. Pharmacol. Biochem. Behav. 59 729–735. 10.1016/S0091-3057(97)00553-4 [DOI] [PubMed] [Google Scholar]
  84. Karlsson M. P., Frank L. M. (2009). Awake replay of remote experiences in the hippocampus. Nat. Neurosci. 12 913–918. 10.1038/nn.2344 [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Khaliq S., Haider S., Ahmed S. P., Perveen T., Haleem D. J. (2006). Relationship of brain tryptophan and serotonin in improving cognitive performance in rats. Pak. J. Pharm. Sci. 19 11–15. [PubMed] [Google Scholar]
  86. Kim J. J., Fanselow M. S. (1992). Modality-specific retrograde amnesia of fear. Science 256 675–677. 10.1126/science.1585183 [DOI] [PubMed] [Google Scholar]
  87. Kometer M., Schmidt A., Jancke L., Vollenweider F. X. (2013). Activation of serotonin 2A receptors underlies the psilocybin-induced effects on alpha oscillations, N170 visual-evoked potentials, and visual hallucinations. J. Neurosci. 33 10544–10551. 10.1523/JNEUROSCI.3007-12.2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Kroeze W. K., Roth B. L. (1998). The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biol. Psychiatry 44 1128–1142. 10.1016/S0006-3223(98)00132-2 [DOI] [PubMed] [Google Scholar]
  89. Kurrasch-Orbaugh D. M., Parrish J. C., Watts V. J., Nichols D. E. (2003a). A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. J. Neurochem. 86 980–991. 10.1046/j.1471-4159.2003.01921.x [DOI] [PubMed] [Google Scholar]
  90. Kurrasch-Orbaugh D. M., Watts V. J., Barker E. L., Nichols D. E. (2003b). Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J. Pharmacol. Exp. Ther. 304 229–237. 10.1124/jpet.102.042184 [DOI] [PubMed] [Google Scholar]
  91. Ledgerwood L., Richardson R., Cranney J. (2003). Effects of D-cycloserine on extinction of conditioned freezing. Behav. Neurosci. 117 341–349. 10.1037/0735-7044.117.2.341 [DOI] [PubMed] [Google Scholar]
  92. Levkovitz Y., Ophir-Shaham O., Bloch Y., Treves I., Fennig S., Grauer E. (2003). Effect of L-tryptophan on memory in patients with schizophrenia. J. Nerv. Ment. Dis. 191 568–573. 10.1097/01.nmd.0000087182.29781.e0 [DOI] [PubMed] [Google Scholar]
  93. Li J. X., Shah A. P., Patel S. K., Rice K. C., France C. P. (2013). Modification of the behavioral effects of morphine in rats by serotonin 5-HT(1)A and 5-HT(2)A receptor agonists: antinociception, drug discrimination, and locomotor activity. Psychopharmacology (Berl) 225 791–801. 10.1007/s00213-012-2870-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Li L. B., Zhang L., Sun Y. N., Han L. N., Wu Z. H., Zhang Q. J., et al. (2015). Activation of serotonin2A receptors in the medial septum-diagonal band of Broca complex enhanced working memory in the hemiparkinsonian rats. Neuropharmacology 91 23–33. 10.1016/j.neuropharm.2014.11.025 [DOI] [PubMed] [Google Scholar]
  95. Lopez-Gimenez J. F., Vilaro M. T., Palacios J. M., Mengod G. (1998). [3H]MDL 100,907 labels 5-HT2A serotonin receptors selectively in primate brain. Neuropharmacology 37 1147–1158. 10.1016/S0028-3908(98)00102-6 [DOI] [PubMed] [Google Scholar]
  96. Lukasiewicz S., Polit A., Kedracka-Krok S., Wedzony K., Mackowiak M., Dziedzicka-Wasylewska M. (2010). Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors. Biochim. Biophys. Acta 1803 1347–1358. 10.1016/j.bbamcr.2010.08.010 [DOI] [PubMed] [Google Scholar]
  97. Luttgen M., Ove Ogren S., Meister B. (2004). Chemical identity of 5-HT2A receptor immunoreactive neurons of the rat septal complex and dorsal hippocampus. Brain Res. 1010 156–165. 10.1016/j.brainres.2004.03.016 [DOI] [PubMed] [Google Scholar]
  98. Marner L., Frokjaer V. G., Kalbitzer J., Lehel S., Madsen K., Baare W. F., et al. (2012). Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer’s disease: a combined [(11)C]DASB and [(18)F]altanserin-PET study. Neurobiol. Aging 33 479–487. 10.1016/j.neurobiolaging.2010.03.023 [DOI] [PubMed] [Google Scholar]
  99. Marner L., Knudsen G. M., Madsen K., Holm S., Baare W., Hasselbalch S. G. (2011). The reduction of baseline serotonin 2A receptors in mild cognitive impairment is stable at two-year follow-up. J. Alzheimers Dis. 23 453–459. [DOI] [PubMed] [Google Scholar]
  100. Masson J., Emerit M. B., Hamon M., Darmon M. (2012). Serotonergic signaling: multiple effectors and pleiotropic effects. Wiley Interdiscip. Rev. Membr. Transp. Signal. 1 685–713. 10.1002/wmts.50 [DOI] [Google Scholar]
  101. Matus-Amat P., Higgins E. A., Barrientos R. M., Rudy J. W. (2004). The role of the dorsal hippocampus in the acquisition and retrieval of context memory representations. J. Neurosci. 24 2431–2439. 10.1523/JNEUROSCI.1598-03.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. McEchron M. D., Bouwmeester H., Tseng W., Weiss C., Disterhoft J. F. (1998). Hippocampectomy disrupts auditory trace fear conditioning and contextual fear conditioning in the rat. Hippocampus 8 638–646. [DOI] [PubMed] [Google Scholar]
  103. McHugh T. J., Blum K. I., Tsien J. Z., Tonegawa S., Wilson M. A. (1996). Impaired hippocampal representation of space in CA1-specific NMDAR1 knockout mice. Cell 87 1339–1349. 10.1016/S0092-8674(00)81828-0 [DOI] [PubMed] [Google Scholar]
  104. McLean J. H., Darby-King A., Hodge E. (1996). 5-HT2 receptor involvement in conditioned olfactory learning in the neonate rat pup. Behav. Neurosci. 110 1426–1434. 10.1037/0735-7044.110.6.1426 [DOI] [PubMed] [Google Scholar]
  105. Melancon B. J., Hopkins C. R., Wood M. R., Emmitte K. A., Niswender C. M., Christopoulos A., et al. (2012). Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J. Med. Chem. 55 1445–1464. 10.1021/jm201139r [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Meller R., Harrison P. J., Elliott J. M., Sharp T. (2002). In vitro evidence that 5-hydroxytryptamine increases efflux of glial glutamate via 5-HT(2A) receptor activation. J. Neurosci. Res. 67 399–405. 10.1002/jnr.10126 [DOI] [PubMed] [Google Scholar]
  107. Meltzer C. C., Smith G., Dekosky S. T., Pollock B. G., Mathis C. A., Moore R. Y., et al. (1998). Serotonin in aging, late-life depression, and Alzheimer’s disease: the emerging role of functional imaging. Neuropsychopharmacology 18 407–430. 10.1016/S0893-133X(97)00194-2 [DOI] [PubMed] [Google Scholar]
  108. Meltzer H. Y. (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21 106S–115S. 10.1016/S0893-133X(99)00046-9 [DOI] [PubMed] [Google Scholar]
  109. Meneses A. (2007). Stimulation of 5-HT1A, 5-HT1B, 5-HT2A/2C, 5-HT3 and 5-HT4 receptors or 5-HT uptake inhibition: short- and long-term memory. Behav. Brain Res. 184 81–90. 10.1016/j.bbr.2007.06.026 [DOI] [PubMed] [Google Scholar]
  110. Meneses A. (2013). 5-HT systems: emergent targets for memory formation and memory alteration. Rev. Neurosci. 24 629–664. 10.1515/revneuro-2013-0026 [DOI] [PubMed] [Google Scholar]
  111. Meneses A., Terron J. A., Hong E. (1997). Effects of the 5-HT receptor antagonists GR127935 (5-HT1B/1D) and MDL100907 (5-HT2A) in the consolidation of learning. Behav. Brain Res. 89 217–223. 10.1016/S0166-4328(97)00055-7 [DOI] [PubMed] [Google Scholar]
  112. Millan M. J., Marin P., Bockaert J., Mannoury La Cour C. (2008). Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol. Sci. 29 454–464. 10.1016/j.tips.2008.06.007 [DOI] [PubMed] [Google Scholar]
  113. Miner L. A., Backstrom J. R., Sanders-Bush E., Sesack S. R. (2003). Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience 116 107–117. 10.1016/S0306-4522(02)00580-8 [DOI] [PubMed] [Google Scholar]
  114. Mirjana C., Baviera M., Invernizzi R. W., Balducci C. (2004). The serotonin 5-HT2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex. Neuropsychopharmacology 29 1637–1647. 10.1038/sj.npp.1300479 [DOI] [PubMed] [Google Scholar]
  115. Morris R. (1984). Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11 47–60. 10.1016/0165-0270(84)90007-4 [DOI] [PubMed] [Google Scholar]
  116. Morris R. G., Garrud P., Rawlins J. N., O’keefe J. (1982). Place navigation impaired in rats with hippocampal lesions. Nature 297 681–683. 10.1038/297681a0 [DOI] [PubMed] [Google Scholar]
  117. Moser E. I., Kropff E., Moser M. B. (2008). Place cells, grid cells, and the brain’s spatial representation system. Annu. Rev. Neurosci. 31 69–89. 10.1146/annurev.neuro.31.061307.090723 [DOI] [PubMed] [Google Scholar]
  118. Naghdi N., Harooni H. E. (2005). The effect of intrahippocampal injections of ritanserin (5HT2A/2C antagonist) and granisetron (5HT3 antagonist) on learning as assessed in the spatial version of the water maze. Behav. Brain Res. 157 205–210. 10.1016/j.bbr.2004.06.024 [DOI] [PubMed] [Google Scholar]
  119. Nic Dhonnchadha B. A., Fox R. G., Stutz S. J., Rice K. C., Cunningham K. A. (2009). Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model. Behav. Neurosci. 123 382–396. 10.1037/a0014592 [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. O’Neill M. F., Heron-Maxwell C. L., Shaw G. (1999). 5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB. Pharmacol. Biochem. Behav. 63 237–243. 10.1016/S0091-3057(98)00240-8 [DOI] [PubMed] [Google Scholar]
  121. Pazos A., Probst A., Palacios J. M. (1987). Serotonin receptors in the human brain–IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 21 123–139. 10.1016/0306-4522(87)90327-7 [DOI] [PubMed] [Google Scholar]
  122. Peddie C. J., Davies H. A., Colyer F. M., Stewart M. G., Rodriguez J. J. (2008). Colocalisation of serotonin2A receptors with the glutamate receptor subunits NR1 and GluR2 in the dentate gyrus: an ultrastructural study of a modulatory role. Exp. Neurol. 211 561–573. 10.1016/j.expneurol.2008.03.003 [DOI] [PubMed] [Google Scholar]
  123. Perani D., Garibotto V., Gorini A., Moresco R. M., Henin M., Panzacchi A., et al. (2008). In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage 42 306–314. 10.1016/j.neuroimage.2008.04.233 [DOI] [PubMed] [Google Scholar]
  124. Peroutka S. J., Snyder S. H. (1979). Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol. Pharmacol. 16 687–699. [PubMed] [Google Scholar]
  125. Phillips R. G., LeDoux J. E. (1992). Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav. Neurosci. 106 274–285. 10.1037/0735-7044.106.2.274 [DOI] [PubMed] [Google Scholar]
  126. Pockros L. A., Pentkowski N. S., Swinford S. E., Neisewander J. L. (2011). Blockade of 5-HT2A receptors in the medial prefrontal cortex attenuates reinstatement of cue-elicited cocaine-seeking behavior in rats. Psychopharmacology (Berl) 213 307–320. 10.1007/s00213-010-2071-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Porter R. J., Lunn B. S., O’brien J. T. (2003). Effects of acute tryptophan depletion on cognitive function in Alzheimer’s disease and in the healthy elderly. Psychol. Med. 33 41–49. 10.1017/s0033291702006906 [DOI] [PubMed] [Google Scholar]
  128. Poyurovsky M., Koren D., Gonopolsky I., Schneidman M., Fuchs C., Weizman A., et al. (2003). Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur. Neuropsychopharmacol. 13 123–128. 10.1016/S0924-977X(02)00155-4 [DOI] [PubMed] [Google Scholar]
  129. Preston A. R., Eichenbaum H. (2013). Interplay of hippocampus and prefrontal cortex in memory. Curr. Biol. 23 R764–R773. 10.1016/j.cub.2013.05.041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Pritchett D. B., Bach A. W., Wozny M., Taleb O., Dal Toso R., Shih J. C., et al. (1988). Structure and functional expression of cloned rat serotonin 5HT-2 receptor. EMBO J. 7 4135–4140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Quinn J. C., Johnson-Farley N. N., Yoon J., Cowen D. S. (2002). Activation of extracellular-regulated kinase by 5-hydroxytryptamine(2A) receptors in PC12 cells is protein kinase C-independent and requires calmodulin and tyrosine kinases. J. Pharmacol. Exp. Ther. 303 746–752. 10.1124/jpet.102.038083 [DOI] [PubMed] [Google Scholar]
  132. Quirion R., Richard J., Dam T. V. (1985). Evidence for the existence of serotonin type-2 receptors on cholinergic terminals in rat cortex. Brain Res. 333 345–349. 10.1016/0006-8993(85)91590-2 [DOI] [PubMed] [Google Scholar]
  133. Quirk G. J., Pare D., Richardson R., Herry C., Monfils M. H., Schiller D., et al. (2010). Erasing fear memories with extinction training. J. Neurosci. 30 14993–14997. 10.1523/JNEUROSCI.4268-10.2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  134. Rambousek L., Palenicek T., Vales K., Stuchlik A. (2014). The effect of psilocin on memory acquisition, retrieval, and consolidation in the rat. Front. Behav. Neurosci. 8:180 10.3389/fnbeh.2014.00180 [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. Rios C. D., Jordan B. A., Gomes I., Devi L. A. (2001). G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol. Ther. 92 71–87. 10.1016/S0163-7258(01)00160-7 [DOI] [PubMed] [Google Scholar]
  136. Romano A. G., Quinn J. L., Li L., Dave K. D., Schindler E. A., Aloyo V. J., et al. (2010). Intrahippocampal LSD accelerates learning and desensitizes the 5-HT(2A) receptor in the rabbit, Romano et al. Psychopharmacology (Berl) 212 441–448. 10.1007/s00213-010-2004-7 [DOI] [PubMed] [Google Scholar]
  137. Roth B. L., Berry S. A., Kroeze W. K., Willins D. L., Kristiansen K. (1998). Serotonin 5-HT2A receptors: molecular biology and mechanisms of regulation. Crit. Rev. Neurobiol. 12 319–338. 10.1615/CritRevNeurobiol.v12.i4.30 [DOI] [PubMed] [Google Scholar]
  138. Rudy J. W., Barrientos R. M., O’reilly R. C. (2002). Hippocampal formation supports conditioning to memory of a context. Behav. Neurosci. 116 530–538. 10.1037/0735-7044.116.4.530 [DOI] [PubMed] [Google Scholar]
  139. Rudy J. W., Huff N. C., Matus-Amat P. (2004). Understanding contextual fear conditioning: insights from a two-process model. Neurosci. Biobehav. Rev. 28 675–685. 10.1016/j.neubiorev.2004.09.004 [DOI] [PubMed] [Google Scholar]
  140. Ruotsalainen S., Sirvio J., Jakala P., Puumala T., Macdonald E., Riekkinen P. Sr. (1997). Differential effects of three 5-HT receptor antagonists on the performance of rats in attentional and working memory tasks. Eur. Neuropsychopharmacol. 7 99–108. 10.1016/S0924-977X(96)00389-6 [DOI] [PubMed] [Google Scholar]
  141. Santhosh L., Estok K. M., Vogel R. S., Tamagnan G. D., Baldwin R. M., Mitsis E. M., et al. (2009). Regional distribution and behavioral correlates of 5-HT(2A) receptors in Alzheimer’s disease with [(18)F]deuteroaltanserin and PET. Psychiatry Res. 173 212–217. 10.1016/j.pscychresns.2009.03.007 [DOI] [PubMed] [Google Scholar]
  142. Schmid C. L., Bohn L. M. (2010). Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ss-arrestin2/Src/Akt signaling complex in vivo. J. Neurosci. 30 13513–13524. 10.1523/JNEUROSCI.1665-10.2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  143. Schmid C. L., Raehal K. M., Bohn L. M. (2008). Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc. Natl. Acad. Sci. U.S.A. 105 1079–1084. 10.1073/pnas.0708862105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  144. Schmitt J. A., Wingen M., Ramaekers J. G., Evers E. A., Riedel W. J. (2006). Serotonin and human cognitive performance. Curr. Pharm. Des. 12 2473–2486. 10.2174/138161206777698909 [DOI] [PubMed] [Google Scholar]
  145. Schott B. H., Seidenbecher C. I., Richter S., Wustenberg T., Debska-Vielhaber G., Schubert H., et al. (2011). Genetic variation of the serotonin 2a receptor affects hippocampal novelty processing in humans. PLoS ONE 6:e15984 10.1371/journal.pone.0015984 [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Sheffler D. J., Kroeze W. K., Garcia B. G., Deutch A. Y., Hufeisen S. J., Leahy P., et al. (2006). p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signaling. Proc. Natl. Acad. Sci. U.S.A. 103 4717–4722. 10.1073/pnas.0600585103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  147. Shi J., Damjanoska K. J., Singh R. K., Carrasco G. A., Garcia F., Grippo A. J., et al. (2007). Agonist induced-phosphorylation of Galpha11 protein reduces coupling to 5-HT2A receptors. J. Pharmacol. Exp. Ther. 323 248–256. 10.1124/jpet.107.122317 [DOI] [PubMed] [Google Scholar]
  148. Sierra-Mercado D., Padilla-Coreano N., Quirk G. J. (2011). Dissociable roles of prelimbic and infralimbic cortices, ventral hippocampus, and basolateral amygdala in the expression and extinction of conditioned fear. Neuropsychopharmacology 36 529–538. 10.1038/npp.2010.184 [DOI] [PMC free article] [PubMed] [Google Scholar]
  149. Sigmund J. C., Vogler C., Huynh K. D., De Quervain D. J., Papassotiropoulos A. (2008). Fine-mapping at the HTR2A locus reveals multiple episodic memory-related variants. Biol. Psychol. 79 239–242. 10.1016/j.biopsycho.2008.06.002 [DOI] [PubMed] [Google Scholar]
  150. Singh R. K., Jia C., Garcia F., Carrasco G. A., Battaglia G., Muma N. A. (2010). Activation of the JAK-STAT pathway by olanzapine is necessary for desensitization of serotonin2A receptor-stimulated phospholipase C signaling in rat frontal cortex but not serotonin2A receptor-stimulated hormone release. J. Psychopharmacol. 24 1079–1088. 10.1177/0269881109103090 [DOI] [PMC free article] [PubMed] [Google Scholar]
  151. Snigdha S., Horiguchi M., Huang M., Li Z., Shahid M., Neill J. C., et al. (2010). Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J. Pharmacol. Exp. Ther. 332 622–631. 10.1124/jpet.109.156349 [DOI] [PubMed] [Google Scholar]
  152. Sparkes R. S., Lan N., Klisak I., Mohandas T., Diep A., Kojis T., et al. (1991). Assignment of a serotonin 5HT-2 receptor gene (HTR2) to human chromosome 13q14-q21 and mouse chromosome 14. Genomics 9 461–465. 10.1016/0888-7543(91)90411-7 [DOI] [PubMed] [Google Scholar]
  153. Squire L. R., Stark C. E., Clark R. E. (2004). The medial temporal lobe. Annu. Rev. Neurosci. 27 279–306. 10.1146/annurev.neuro.27.070203.144130 [DOI] [PubMed] [Google Scholar]
  154. Squire L. R., Wixted J. T., Clark R. E. (2007). Recognition memory and the medial temporal lobe: a new perspective. Nat. Rev. Neurosci. 8 872–883. 10.1038/nrn2154 [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Stein C., Davidowa H., Albrecht D. (2000). 5-HT(1A) receptor-mediated inhibition and 5-HT(2) as well as 5-HT(3) receptor-mediated excitation in different subdivisions of the rat amygdala. Synapse 38 328–337. [DOI] [PubMed] [Google Scholar]
  156. Stiedl O., Birkenfeld K., Palve M., Spiess J. (2000). Impairment of conditioned contextual fear of C57BL/6J mice by intracerebral injections of the NMDA receptor antagonist APV. Behav. Brain Res. 116 157–168. 10.1016/S0166-4328(00)00269-2 [DOI] [PubMed] [Google Scholar]
  157. Strachan R. T., Allen J. A., Sheffler D. J., Roth B. L. (2010). p90 Ribosomal S6 kinase 2, a novel GPCR kinase, is required for growth factor-mediated attenuation of GPCR signaling. Biochemistry 49 2657–2671. 10.1021/bi901921k [DOI] [PMC free article] [PubMed] [Google Scholar]
  158. Strachan R. T., Allen J. A., Sheffler D. J., Willard B., Kinter M., Kiselar J. G., et al. (2009). Ribosomal S6 kinase 2 directly phosphorylates the 5-hydroxytryptamine 2A (5-HT2A) serotonin receptor, thereby modulating 5-HT2A signaling. J. Biol. Chem. 284 5557–5573. 10.1074/jbc.M805705200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  159. Szapiro G., Vianna M. R., Mcgaugh J. L., Medina J. H., Izquierdo I. (2003). The role of NMDA glutamate receptors, PKA, MAPK, and CAMKII in the hippocampus in extinction of conditioned fear. Hippocampus 13 53–58. 10.1002/hipo.10043 [DOI] [PubMed] [Google Scholar]
  160. Talvik-Lotfi M., Nyberg S., Nordstrom A. L., Ito H., Halldin C., Brunner F., et al. (2000). High 5HT2A receptor occupancy in M100907-treated schizophrenic patients. Psychopharmacology (Berl) 148 400–403. 10.1007/s002130050069 [DOI] [PubMed] [Google Scholar]
  161. Thomas E. A., Carson M. J., Neal M. J., Sutcliffe J. G. (1997). Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc. Natl. Acad. Sci. U.S.A. 94 14115–14119. 10.1073/pnas.94.25.14115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  162. Tovote P., Fadok J. P., Luthi A. (2015). Neuronal circuits for fear and anxiety. Nat. Rev. Neurosci. 16 317–331. 10.1038/nrn3945 [DOI] [PubMed] [Google Scholar]
  163. Turner J. H., Raymond J. R. (2005). Interaction of calmodulin with the serotonin 5-hydroxytryptamine2A receptor. A putative regulator of G protein coupling and receptor phosphorylation by protein kinase C. J. Biol. Chem. 280 30741–30750. 10.1074/jbc.M501696200 [DOI] [PubMed] [Google Scholar]
  164. Uchida S., Umeeda H., Kitamoto A., Masushige S., Kida S. (2007). Chronic reduction in dietary tryptophan leads to a selective impairment of contextual fear memory in mice. Brain Res. 1149 149–156. 10.1016/j.brainres.2007.02.049 [DOI] [PubMed] [Google Scholar]
  165. Vaidya V. A., Marek G. J., Aghajanian G. K., Duman R. S. (1997). 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J. Neurosci. 17 2785–2795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  166. Versijpt J., Van Laere K. J., Dumont F., Decoo D., Vandecapelle M., Santens P., et al. (2003). Imaging of the 5-HT2A system: age-, gender-, and Alzheimer’s disease-related findings. Neurobiol. Aging 24 553–561. 10.1016/S0197-4580(02)00137-9 [DOI] [PubMed] [Google Scholar]
  167. Vertes R. P. (1991). A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat. J. Comp. Neurol. 313 643–668. 10.1002/cne.903130409 [DOI] [PubMed] [Google Scholar]
  168. Vertes R. P., Fortin W. J., Crane A. M. (1999). Projections of the median raphe nucleus in the rat. J. Comp. Neurol. 407 555–582. [DOI] [PubMed] [Google Scholar]
  169. Vinals X., Moreno E., Lanfumey L., Cordomi A., Pastor A., De La Torre R., et al. (2015). Cognitive impairment induced by delta9-tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors. PLoS Biol. 13:e1002194 10.1371/journal.pbio.1002194 [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Wagner M., Schuhmacher A., Schwab S., Zobel A., Maier W. (2008). The His452Tyr variant of the gene encoding the 5-HT2A receptor is specifically associated with consolidation of episodic memory in humans. Int. J. Neuropsychopharmacol. 11 1163–1167. 10.1017/S146114570800905X [DOI] [PubMed] [Google Scholar]
  171. Walker D. L., Ressler K. J., Lu K. T., Davis M. (2002). Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J. Neurosci. 22 2343–2351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  172. Watts S. W. (1998). Activation of the mitogen-activated protein kinase pathway via the 5-HT2A receptor. Ann. N. Y. Acad. Sci. 861 162–168. 10.1111/j.1749-6632.1998.tb10187.x [DOI] [PubMed] [Google Scholar]
  173. Welsh S. E., Romano A. G., Harvey J. A. (1998). Effects of serotonin 5-HT(2A/2C) antagonists on associative learning in the rabbit. Psychopharmacology (Berl) 137 157–163. 10.1007/s002130050605 [DOI] [PubMed] [Google Scholar]
  174. Williams G. V., Rao S. G., Goldman-Rakic P. S. (2002). The physiological role of 5-HT2A receptors in working memory. J. Neurosci. 22 2843–2854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  175. Willins D. L., Deutch A. Y., Roth B. L. (1997). Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27 79–82. [DOI] [PubMed] [Google Scholar]
  176. Wiltgen B. J., Sanders M. J., Anagnostaras S. G., Sage J. R., Fanselow M. S. (2006). Context fear learning in the absence of the hippocampus. J. Neurosci. 26 5484–5491. 10.1523/JNEUROSCI.2685-05.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  177. Xia Z., Gray J. A., Compton-Toth B. A., Roth B. L. (2003). A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. J. Biol. Chem. 278 21901–21908. 10.1074/jbc.M301905200 [DOI] [PubMed] [Google Scholar]
  178. Xu T., Pandey S. C. (2000). Cellular localization of serotonin(2A) (5HT(2A)) receptors in the rat brain. Brain Res. Bull. 51 499–505. 10.1016/S0361-9230(99)00278-6 [DOI] [PubMed] [Google Scholar]
  179. Yoshida H., Kanamaru C., Ohtani A., Li F., Senzaki K., Shiga T. (2011). Subtype specific roles of serotonin receptors in the spine formation of cortical neurons in vitro. Neurosci. Res. 71 311–314. 10.1016/j.neures.2011.07.1824 [DOI] [PubMed] [Google Scholar]
  180. Zaniewska M., Mccreary A. C., Wydra K., Filip M. (2010). Differential effects of serotonin (5-HT)2 receptor-targeting ligands on locomotor responses to nicotine-repeated treatment. Synapse 64 511–519. 10.1002/syn.20756 [DOI] [PubMed] [Google Scholar]
  181. Zayara A. E., Mciver G., Valdivia P. N., Lominac K. D., Mccreary A. C., Szumlinski K. K. (2011). Blockade of nucleus accumbens 5-HT2A and 5-HT2C receptors prevents the expression of cocaine-induced behavioral and neurochemical sensitization in rats. Psychopharmacology (Berl) 213 321–335. 10.1007/s00213-010-1996-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  182. Zelikowsky M., Hersman S., Chawla M. K., Barnes C. A., Fanselow M. S. (2014). Neuronal ensembles in amygdala, hippocampus, and prefrontal cortex track differential components of contextual fear. J. Neurosci. 34 8462–8466. 10.1523/JNEUROSCI.3624-13.2014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  183. Zhang G., Ásgeirsdóttir H. N., Cohen S. J., Munchow A. H., Barrera M. P., Stackman R. W., Jr. (2013). Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL/6J mice. Neuropharmacology 64 403–413. 10.1016/j.neuropharm.2012.06.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  184. Zhang G., Cinalli D., Barrera M. P., Stackman R. W. (2015). “Activation of serotonin 5-HT2A receptor delays the retrieval of spatial memory in a Morris-water maze task,” in Proceedings of the Society of Neuroscience Conference Chicago. [Google Scholar]
  185. Zhou F. M., Hablitz J. J. (1999). Activation of serotonin receptors modulates synaptic transmission in rat cerebral cortex. J. Neurophysiol. 82 2989–2999. [DOI] [PubMed] [Google Scholar]
  186. Zhu B., Chen C., Loftus E. F., Moyzis R. K., Dong Q., Lin C. (2013). True but not false memories are associated with the HTR2A gene. Neurobiol. Learn Mem. 106 204–209. 10.1016/j.nlm.2013.09.004 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES